Drug Wars--A New Generation of Generic Pharmaceutical Delay

Robin C Feldman
Evan Frondorf
ARTICLE

DRUG WARS: A NEW GENERATION OF GENERIC PHARMACEUTICAL DELAY

ROBIN FELDMAN* & EVAN FRONDORF**

Table of Contents

I. INTRODUCTION: HATCH-WAXMAN FACES THE HATCHET ....... 500 R
II. THE WINDING ROAD TO GENERIC ENTRY ................. 506 R
III. “GENERATION 1.0”: THE RISE AND FALL OF TRADITIONAL PAY-FOR-DELAY ......................... 510 R
IV. “GENERATION 2.0”: PAY-FOR-DELAY TAKES NEW, COMPLICATED FORMS ................................. 516 R
   A. Already Steps Ahead of Actavis .................................. 516 R
   B. In re Lipitor: Everything But the Kitchen Sink ........... 517 R
   C. Contract Clauses and King Drug ................................. 521 R
V. “GENERATION 3.0”: PAY-FOR-DELAY REPLACED BY ACTIVE OBSTRUCTION OF GENERICS ...................... 524 R
   A. General Description and the Economics at Play .......... 524 R
   B. Product Hopping and Evergreening ............................ 527 R
   C. REMS-based Delay ............................................... 533 R
   D. Delay via Citizen Petition ...................................... 543 R
   E. Preventing the “Skinny Label”: Blocking Section viii Carve-Outs ................................................. 549 R
VI. CONCLUSION: EARNING A BETTER GRADE FOR HATCH-WAXMAN .................................................. 554 R
   A. Societal Harms ..................................................... 554 R
   B. Systems, Simplification, Sunshine, and Standards-Based Doctrines .............................................. 556 R

Thirty years ago, Congress ushered in a new and miraculous era in medicine with the creation of the Hatch-Waxman system for approval of generic drugs. The progress, however, has not been without resistance. This Article presents an overview of three generations of games pharmaceutical companies play to keep generics off the market and maintain monopoly pricing. In “Generation 1.0,” branded companies simply pay generics to delay entering the market, reaping billions of dollars of benefit. “Generation 2.0” involves paying for delay through multiple side deals that camouflage the value of the payment. Genera-

* Harry and Lillian Hastings Professor of Law and Director of the Institute for Innovation Law, University of California Hastings College of the Law.
** Research Fellow at the Institute for Innovation Law, University of California Hastings College of the Law. We wish to express our thanks to Matt Avery, Scott Hemphill, Cheryl Johnson, Mark Lemley, and Joe Lukens for helpful comments on prior drafts. We are also grateful to Andrew Cordova and Isil Selen Denemec for outstanding research assistance.
tion 2.0 also includes what this Article refers to as “boy scout clauses”—agreements to behave honorably that actually mask anticompetitive collusion. The newest generation, however, moves from collusion to obstruction. Generation 3.0 uses administrative processes, regulatory schemes, and drug modifications to prevent generics from getting to market. Some of these schemes have now made the news as debates rage over pharmaceutical pricing.

Society, however, cannot necessarily blame companies for engaging in behavior that is strongly in their economic self-interest. One cannot expect mice to run in the appropriate direction if the cheese is located at the other end. Thus, this Article’s goals are two-fold: first, to shine light on the complex behaviors as they are unfolding, and second, to explore the contours of how new approaches could be structured. To paraphrase one former FDA commissioner, we do not want the most creative activity at pharmaceutical companies to take place in the legal department. And after thirty years of experience with Hatch-Waxman, it is time for the next phase.

I. INTRODUCTION: HATCH-WAXMAN FACES THE HATCHET

In most pharmaceutical transactions, patients seamlessly realize the benefits of generic drugs. A doctor’s written prescription for Pfizer’s Zoloft is substituted for a generic bottle of sertraline by the time the patient reaches the pharmacy. Patients who present with standard sinus infections will probably leave their neighborhood drug store with the classic five-day boxes of azithromycin for $10, rather than boxes actually branded as a Zithromax Z-Pak. Automatic substitution is led by the pharmacist, who is generally permitted to substitute a generic for a branded drug when available, and the public enjoys billions of dollars of savings with no action required on the part of either patients or doctors. The patient’s incentives are also usually aligned with those of insurers and other payors, who wish to pay less whenever possible and thus heavily promote the use of generics.

Today, 88% of all prescriptions in the U.S. are filled using generic medication, and 81% of all small-molecule drugs have a generic equivalent. When a generic is introduced into a market previously monopolized by a brand-name drug, the generic drug normally enters at a 20% discount from

---


Drug Wars

501

Within six months of launch, the price falls quickly from that point. Eventually, most generics are priced at an 80% to 85% discount from their name-brand equivalents. Prices can even fall to 10% of the original cost when many generics enter the market. Within a year of generic introduction, the name-brand drug generally loses an average of 80% to 90% of its market share. The FDA estimates that consumers saved over $217 billion in 2012 alone through the use of generics, with total savings of $1.68 trillion from 2005 to 2014.

The introduction of generic competitors is tough on a brand-name drug company, which must face the loss of its monopoly status and the resulting severe drop in price. Nevertheless, the design of the patent system dictates that a patent holder’s right to exclude others from the market must end with the expiration of the patent.

One might call the generic revolution a miracle, but it certainly did not occur naturally or serendipitously. The underlying mechanism behind it is particularly complex. Generic drug entry is covered by the Drug Price Competition and Patent Term Restoration Act, commonly known as the Hatch-Waxman Act. Passed in 1984, Hatch-Waxman created a pathway to generic entry meant to incentivize the speedy introduction of generic drugs to market. Before the Act, generic entry into the market was slow. Would-be generic manufacturers could not apply to enter the market until after the branded company’s patents had expired, with the effect that brand-name companies enjoyed a de facto patent extension and ongoing monopoly profits as the generic awaited FDA approval. Further, few generics were entering the market to begin with. The burden of the application process (which

---

5 See id. at 9–10, 10 fig.2.
7 See Berndt & Aitken, supra note 4, at 9, 10 fig.2.
8 See id.; see also Henry G. Grabowski et al., Evolving Brand-Name and Generic Drug Competition May Warrant a Revision of the Hatch-Waxman Act, 30 HEALTH AFF. 2157, 2163 exhibit 4 (2011). In fact, for the period between 2004 and 2008, Grabowski et al. found that the average drug with more than $1 billion in annual sales had more than ten generic competitors one year after first generic entry. See id. at 2160 exhibit 1.
required the generic to complete its own clinical trials) and the lack of substantial profits deterred most manufacturers.\textsuperscript{14}

As discussed in more detail in Part II, Hatch-Waxman offers generics a number of incentives to enter the market as quickly as possible. First, pharmaceutical firms can submit an abbreviated new drug application (“ANDA”) before the patents for the brand-name drug have expired.\textsuperscript{15} ANDAs only need to contain evidence that the generic is bioequivalent and has the same pharmacokinetic profile as the brand-name drug; they can rely on the brand-name drug company’s clinical trial data to meet the rest of the application requirements, including those related to the safety and efficacy of the drug.\textsuperscript{16} Second, in what is known as a Paragraph IV certification, a generic manufacturer can attempt to enter the market before the pioneer’s patent term(s) have expired, generally triggering litigation from the branded firm.\textsuperscript{17} As a reward for facing the costs and risks of litigation, the first generic manufacturer to file a Paragraph IV ANDA and gain approval generally is entitled to 180 days of market exclusivity alongside the brand-name drug.\textsuperscript{18} In other words, during the 180-day period, only the brand-name drug and the first generic filer are allowed to be on the market. While only six months long, this duopoly period can be extremely valuable, worth hundreds of millions of dollars for blockbuster drugs.\textsuperscript{19} This benefit is intended to give generic companies an incentive to challenge weak patents or patents that should not cover the drug at issue.

The Hatch-Waxman Act has overwhelmingly met Congress’ goals of balancing adequate patent protection for pioneer inventors with promoting the rapid introduction of generics once this patent protection has expired. Since 1984, more than 10,000 generics have entered the market,\textsuperscript{20} and the percentage of prescriptions filled with generics has risen from just 13% in 1980\textsuperscript{21} to around 86% by 2013.\textsuperscript{22} Most important, generic manufacturers have the incentive and ability to enter the market immediately after (or even before) the original patent terms expire.

\textsuperscript{21}CONG. BUDGET OFFICE, HOW INCREASED COMPETITION FROM GENERIC DRUGS HAS AFFECTED PRICES AND RETURNS IN THE PHARMACEUTICAL INDUSTRY 37 (1998).
\textsuperscript{22}IMS INST. FOR HEALTHCARE INFORMATICS, supra note 1, at 51.
The actual miracle, however, is not the dramatic rise of generics. Rather, the miracle is that the benefits of Hatch-Waxman have largely held up despite its complexity and the persistent attempts at undercutting its aims. Hatch-Waxman has created a veritable playground of opportunities that pharmaceutical companies have used to hold off generic competition. This is understandable. The temptation to avoid the impact of Hatch-Waxman can be overpowering when even a few months of additional monopoly profits can be worth hundreds of millions of dollars or more. This encourages companies to expend tremendous energy blocking generic entry by any means possible, with some companies using ever more clever and complicated strategies. As a result, many pharmaceutical firms may no longer compete solely on the basis of innovation, but rather on their ability to manipulate policy mechanisms and pathways to extend monopoly and monopoly terms.

This behavior undermines the goals of the patent system and can provide less than optimal innovation effects. One cannot fully blame companies, however, for engaging in behavior that is strongly in their economic self-interests. If society wishes its interests to prevail, then the legal system must bring the incentives of the players into proper alignment with the goals of society—either by creating sufficient incentives or sufficient disincentives. One cannot expect the rats in the maze to run in the direction society wishes if the cheese is located at the other end. And, as the system currently operates, the cheese is poorly located.

The goal of this paper is two-fold: first, to shine light on complex behaviors as they are unfolding and, second, to suggest ways to cabin those behaviors and create incentives for companies to follow the path that is optimal for society. Pharmaceutical companies should be directing their creative energies toward research and development, not toward inventing new legal challenges and regulatory obstructions.

To be clear, when pharmaceutical companies preserve their hard-earned patent exclusivity by legally knocking down generic challenges, such behavior is consistent with societal goals and important for the patent system. Rights are worth little if the rights-holder cannot enforce them, and that is as true for patents as for any form of legal right. In contrast, when firms attempt to unlawfully extend their monopolies, such behavior undercuts the goals of the patent system, and the cost to society can be troubling. Patients and the general public lose, giving up billions of dollars in savings while...

---

ready-to-market generics languish on the sidelines. The energy spent on manipulation of the legal system diverts time and resources away from innovation activities.

This Article presents a broad overview of the “games” pharmaceutical companies play to keep valuable generics away from consumers while enriching their own profits. Some basic “pay-for-delay” strategies have existed since the inception of Hatch-Waxman, but recent judicial scrutiny has driven firms to undertake micro-level delay strategies with a lower chance of success and less lucrative returns. Despite the decreased gains that remain from delay tactics, however, any delay remains valuable. In addition, while early tactics benefitted both pioneer and generic manufacturers, new approaches focus on the active obstruction of generic entry by branded firms, somewhat like tripping other kids on their way to the playground. These new, combative strategies make up the focus of this Article.

This Article proceeds in five Parts. Part II explains the Hatch-Waxman Act pathway to generic entry in more detail, discussing the economic forces of the pharmaceutical market and amendments designed to improve the functioning of the Act. Part III discusses the origins of generic delay tactics, called “Generation 1.0”—the first of three “generations” the Article uses to categorize the tactics that have evolved over time. The organizational system of generations is not meant to suggest that these each of these periods has taken place sequentially and separately. Some “Generation 1.0”-style settlements still survive; early “Generation 3.0” tactics have plagued generics for more than a decade—the overlap between generations can be substantial. Instead, the system serves as a helpful way of organizing sets of related tactics, and the use of “generations” implies that each era of tactics has evolved from or developed in response to strategies from previous generations.

In Generation 1.0, delay generally takes the form of “pay-for-delay” settlements, in which a potential generic manufacturer is simply paid by the pioneer drug maker to refrain from entering the market until a stipulated date. These settlements were commonplace for many years, but the Supreme Court’s 2013 ruling in *FTC v. Actavis* opened the door to antitrust scrutiny of such agreements. As described below, a recent state court decision and a large FTC settlement may signal the end of basic pay-for-delay.

Part IV details the rise of a new generation of pay-for-delay tactics—“Generation 2.0.” Beginning long before *Actavis*, these strategies generally involve the transfer of benefits from the branded firm to a generic manufacturer, but not through a simple cash settlement. Generation 2.0 agreements include patterns of multiple side deals, where two companies settle a number of Hatch-Waxman disputes at once, resulting in a net benefit for the generic firm but without any large, conspicuous payment. Other instruments include overvalued agreements wherein the generic delays entry, but it is paid handsomely to promote, manufacture, or otherwise assist the brand-name company with the sale of its drug. Finally, Generation 2.0 includes “boy scout
Drug Wars

clauses”—agreements to behave honorably that actually mask anticompetitive collusion. As described in Part IV, these side deals are now themselves facing antitrust scrutiny in the courts.

Part V provides a comprehensive look at emerging “Generation 3.0” strategies—tactics that, so far, have been deployed largely under the radar. By detailing this new generation of difficult-to-detect behaviors, the hope is that policymakers and academics can develop appropriate responses to the entire panoply of Hatch-Waxman manipulation. Generation 3.0 tactics no longer focus on delay agreements with generic competitors, but rather on using administrative processes, regulatory schemes with connections to Hatch-Waxman, and drug modifications to obstruct generics from getting to market. Many of these strategies have little justification beyond obstruction of generics, and some recent fact patterns are falling further outside the boundaries of common sense. Specifically, Part V will discuss delay mechanisms including labeling changes, using FDA safety restrictions as an excuse for delay, and sham litigation, as well as “multiplicity tactics,” in which a number of these mechanisms are exploited at once. Some of these strategies have been part of recent schemes to restrict generic substitution while simultaneously raising prices of the brand-name drug, leading to a swell of public outrage in fall 2015 and the return of pharmaceuticals as a key policy topic.

Of course, once companies develop new obstacle strategies, they can also be bargained away, and we are beginning to see new settlement agreements to that effect. Once again, the brand-name drug company can play the “boy scout,” agreeing to behave well but doing it in a way that colludes with the first generic filer against other generics that might lower the price for consumers.

Part VI concludes with ideas for reforming the generic entry pathway. These ideas borrow from systems theory—looking from the perspective of how different systems interact to create opportunities and incentives to correct suboptimal behaviors. Moreover, to move the system away from hide-and-seek games, this section proposes the addition of standards-based legal rules. Most important, to avoid “death by tinkering”24—that is, adjusting doctrines a little here and a little there without comprehensive logic until the entire area collapses under its own weight—this section suggests a deeper look and a more comprehensive overhaul of different intersecting regimes. Hatch-Waxman was indeed a brilliant legislative innovation, heralding nothing short of a miracle in the reduction of drug costs. Now, it is time to consider the next generation of the regime so those miracles are not swept away.25

25 See generally Aaron S. Kesselheim & Jonathan J. Darrow, Hatch-Waxman Turns 30: Do We Need a Re-Designed Approach for the Modern Era?, 15 YALE J. HEALTH POL’Y L. &
II. THE WINDING ROAD TO GENERIC ENTRY

The Hatch-Waxman Act is a deeply complex piece of legislation, codified in four different sections of the United States Code. While it creates a streamlined pathway for generic manufacturers to seek approval of their drug, it does so in a way that testifies to the difficulty of satisfying all stakeholders in the pharmaceutical market. The goal of protecting innovative activity, balanced with the desire to make low-cost drugs available to patients, has produced a labyrinthine series of statutes. Complexity breeds opportunity, however, and Hatch-Waxman’s legacy is littered with evidence of manipulation.

This Part focuses on the core components of Hatch-Waxman most often implicated in generic delay, in the clearest terms possible, omitting discussions of exceptions and complex subsections where appropriate. Later Parts of this Article will introduce other sections of the Act when needed to help make sense of these intricate games of generic delay, including descriptions of amendments meant to tighten the functioning of Hatch-Waxman (while frequently creating their own difficulties).

Hatch-Waxman created a new framework for the approval and marketing of generic medications. Prospective generic manufacturers can submit an Abbreviated New Drug Application, almost exclusively referred to as an “ANDA,” to seek approval of a drug equivalent to a reference drug already approved by the FDA. The ANDA must be for a medication bioequivalent to the brand-name drug, and it must generally have the same active ingredient, route of administration, dosage form, strength, use indications, and labeling information as the existing medication. An ANDA, however, can make use of a branded drug company’s pre-existing clinical trial data that proves the safety and efficacy of the drug. This saves the applicant the years of work and great expense necessary to conduct new clinical trials.

The Hatch-Waxman Act expressly allows the activity necessary to produce an ANDA to take place without triggering an act of patent infringement. The use of the patent holder’s data and trial information, as well as samples of the actual drug to test for bioequivalence, are all exempt from an assertion of patent infringement when used for ANDA development.

---

ETHICS 293 (2015) (presenting another recent article reviewing the history of Hatch-Waxman and suggesting improvements).


27 Feldman, supra note 13, at 160 (“As so often is the case, complexity breeds opportunity, and clever lawyers have been exploiting the details of the act since its inception.”).


31 See Schacht & Thomas, supra note 12, at 1.

exemption allows generics to be ready for entry by the moment of patent expiration at the latest, rather than having to wait for patent expiration and only then begin the process for approval. Prior to Hatch-Waxman, brand-name drug companies enjoyed a lengthened patent term because no generic could be ready to market when the patent expired.33

When the brand-name drug company originally files for FDA approval, the law requires that the company list all patents that “could reasonably be asserted” against a generic applicant.34 These are then recorded in an FDA document commonly referred to as the “Orange Book.”35 The Orange Book has played a prominent role in some of the game playing that has unfolded across time, as described below.

When a generic drug maker files an ANDA, it must make one of four “certifications” to each of the patents the brand-name drug maker has listed for the medication in the Orange Book.36 Most of these certifications result in limited fuss and bother because they either represent that all the patents have expired, that no patents are listed in the Orange Book, or that the generic company will wait until all patents expire before bringing the drug to market.37

All the action, however, is in what is known as a “Paragraph IV certification.” A Paragraph IV certification alleges that the listed patent is either invalid or would not be infringed by the generic drug.38 In essence, this represents an attempt by the generic to enter the market before expiration of a listed Orange Book patent, and it is the core mechanism of Hatch-Waxman. The entire Paragraph IV process is intended to encourage generic companies to challenge weak patents as well as to give generics the incentive to do battle with big pharmaceutical companies.

A Paragraph IV certification is treated as an “artificial” act of patent infringement. This allows the brand-name drug company to initiate litigation, which it must do within forty-five days of receiving notification from the ANDA filer. Otherwise, the FDA may approve the application.39

33 See Roche Prods., Inc. v. Bolar Pharm. Co., 733 F.2d 858, 863–64 (Fed. Cir. 1984) (“The [brand-name companies] gain for themselves, it is asserted, a de facto monopoly of upwards of 2 years by enjoining FDA-required testing of a generic drug until the patent on the drug’s active ingredient expires.”). The case found that use of a patent-protected drug for the tests necessary for generic development was a prohibited use. Hatch-Waxman was signed into law five months later.


Why would a generic applicant purposely choose to bring on costly and potentially damaging litigation? First, there are certainly weak patent claims, and generic companies have enjoyed considerable success challenging drug patents. Second, baked into Hatch-Waxman is a significant incentive for the first filer submitting a generic application with a Paragraph IV certification to at least one of the listed patents for the drug: as long as the first filer does not lose its patent infringement case, it is generally entitled to 180 days of marketing exclusivity alongside the brand-name drug. In other words, for about six months, only the brand-name drug company and the first generic can sell the drug; no other generic company can come to market. This essentially creates a duopoly between the brand and generic for the first 180 days after the generic enters, which normally occurs after one of the following events: all relevant patents and exclusivities expire; the generic drug maker wins a challenge invalidating all relevant patents or finding that infringement did not occur; or the generic company reaches a settlement with the branded drug maker allowing entry. This exclusivity period can easily be worth hundreds of millions of dollars to a generic, representing a substantial majority of the potential profits to be gained from generic entry.

The Paragraph IV first-filer exclusivity is thus an enormous incentive for a generic applicant to file as soon as possible and secure the 180 days of exclusivity, as well as potential market entry long before drug patent expiration. The artificial nature of the patent infringement action is also helpful. It allows the generic to trigger litigation without actually entering the market and potentially accruing substantial damages. This complicated and lucrative pathway also has made Hatch-Waxman susceptible to abuse, mainly because of the economic incentives created by the exclusivity period.

41 See 21 U.S.C. § 355(j)(5)(B)(iv) (2012). After 2003 amendments to Hatch-Waxman, it is possible to forfeit the 180-day exclusivity period without losing a patent infringement case. See infra Part III. Further, it is also possible that the brand-name drug company chooses not to bring litigation during the forty-five day period. In this case, the first-filer still retains its rights to 180 days of exclusivity.
42 During the 180-day period, the FDA is not permitted to approve any other generic applications that have a Paragraph IV certification. See 21 U.S.C. §§ 355(j)(5)(B)(iv)(I)–(II) (2012). However, this does not entirely prevent the presence of other competition. Brand-name companies can launch their own generic version of the drug at a lower price tier (or permit another company to do so), creating instant competition for the generic. These generics are often called “authorized generics,” and are discussed infra in Part IV.
43 See Avery, supra note 19, at 178, 178 nn.55–56.
44 When there are multiple first-filing ANDA applicants (all submitting on the same day, usually the first day that ANDAs will be accepted), all applicants are eligible for exclusivity. See generally U.S. Food & Drug Admin., Guidance for Industry 180-Day Exclusivity When Multiple ANDAs Are Submitted on the Same Day (2003), http://www.fda.gov/downloads/drugs/guidanceregulatoryinformation/guidances/ucm072851.pdf [https://perma.cc/PAE4-6LWE].
If the patent holder chooses to initiate litigation, a thirty-month stay is placed on generic approval, with the goal of allowing the infringement litigation to work through the courts while the FDA is reviewing the generic application. The generic application cannot be approved during the following thirty months, unless a court enters a final order declaring the patents at issue invalid, unenforceable, or not infringed.

Although Hatch-Waxman generally is discussed in the framework of generic drugs, the Act also was designed to add new protections for brand-name drug companies. Between the Patent and Trademark Office’s (“PTO”) patent approval process and the FDA’s own approval process for the drug (which generally overlaps with a portion of the patent term), the effective life of a drug patent is often substantially shorter than the twenty-year term of most patents. Thus, Hatch-Waxman allows pharmaceutical companies to receive an extension of the patent term to partially “restore” the time lost to approval processes. This “restoration” is the origin of the Hatch-Waxman Act’s full name, the Drug Price Competition and Patent Term Restoration Act.

The Act also provides certain new drugs with specified non-patent exclusivities. For example, drugs with a new active ingredient never before approved by the FDA are eligible for five years of marketing exclusivity, in what is known as new chemical entity (“NCE”) exclusivity. This is not an extension of the patent term—it only means that the FDA is not allowed to accept applications for generic versions of the drug for at least four years after initial FDA approval. This, however, gives the brand-name drug maker breathing space before a generic company can start the ball rolling. Similar exclusivities are available for new clinical studies that lead to new drug indications or formulations (three years) and, as established by the Orphan Drug Act, drugs with indications to treat defined rare diseases (seven years of marketing exclusivity). A six-month exclusivity extension for all approved indications is available when the drug undergoes pediatric studies requested by the FDA.

---

47 See SCHAFF & THOMAS, supra note 12, at 3.
50 See 21 U.S.C. §§ 355(a)–(c) (2012); see also Kurt R. Karst, Pediatric Exclusivity: Amazingly Powerful, Essentially Ironclad . . . , and Often Overlooked, FDA L. Blog (July 7, 2015, 7:59 PM), http://www.fdalawblog.net/fda_law_blog_hyman_phelps/2015/07/pediatric-
Important changes have been made to Hatch-Waxman and its related mechanisms since its enactment, most notably through the Medicare Modernization Act in 2003 and the Food and Drug Administration Amendments Act of 2007. With many of the changes aimed at curbing abuses and plugging loopholes in Hatch-Waxman, a number of these modifications will be discussed in future Parts when relevant.

In short, Hatch-Waxman set the stage for a new era in medicines: generic competitors were able to develop and test their products, as well as apply for FDA approval, before the expiration of the brand-name drug company’s patent. In addition, the legislation created incentives for generics to challenge weak patent claims. The goal, of course, was to speed generic versions of drugs to market as quickly as possible, introducing competition and dramatically lowering prices for consumers.

III. “Generation 1.0”: The Rise and Fall of Traditional Pay-For-Delay

The new dawn was considerably chillier for brand-name drug companies. Having spent hundreds of millions, if not billions, on research and development, the prospect of losing the additional breathing space of profits loomed large on the horizon. With so much at stake for every moment that one can delay the entry of generic competitors, the strategy of pay-for-delay emerged. It is an ingenious approach in which the brand-name drug company shares a portion of its monopoly profits with the generic company in exchange for the generic company agreeing to stay out of the market. Specifically, in pay-for-delay, the brand-name company settles its Paragraph IV lawsuit with the generic company. Under the terms of the settlement, the generic receives a cash payment and agrees to delay its entry into the market for a specified period of time.

These settlements are sometimes referred to as “reverse payment” schemes, a reference to the fact that payment is transferred from the suing exclusivity-amazingly-powerful-essentially-ironclad-and-often-overlooked.html (noting that pediatric exclusivity also applies to all protected indications and formulations of the reference drug, not just pediatric indications that may exist).


brand-name drug company to the defending generic competitor, countering the standard expectation that a defendant would pay a plaintiff to settle a suit. The practice has come to light as Paragraph IV challenges have significantly increased over the last twenty years\(^5\) and the median time from FDA approval of a brand-name drug to first Paragraph IV challenge by a generic company has dropped dramatically.\(^5\)

With pay-for-delay settlements, the incentives of both the brand-name drug company and the generic company are aligned. In most cases, delaying the entry date does not matter as much to the first generic filer.\(^5\) Demand is relatively inelastic for blockbuster drugs, meaning that annual sales are unlikely to fall sharply before the expiration of the patent term. Thus, as Professor Hemphill notes, as long as a generic first filer is able to enjoy the entire 180-day exclusivity period, the generic does not particularly care if it has to wait until the end of the patent term to do so.\(^5\)

In addition, when the generic eventually enters the market, the competition will drive down the price of the drug substantially and neither company will be able to charge the supracompetitive price that the brand-name drug company enjoyed on its own. Given that delayed entry keeps the price high, the brand-name drug company can “share” some of that monopoly profit in the form of a settlement payment. Thus, with pay-for-delay, the generic gets a share of the profits from monopoly pricing and still eventually gets its 180 days of exclusivity from other generics as well, when it eventually gets to market. Both parties are happy. The biggest loser is destined to be the public, which continues to suffer higher prices during the period of delay. For exam-

---

\(^5\) See C. Scott Hemphill & Bhaven N. Sampat, *When Do Generics Challenge Drug Patents?*, 8 J. EMPIRICAL LEGAL STUD. 613, 624, 624 fig.4 (2011) (finding that by 2009, 22% of drugs approved between 1985 and 1987 were subject to a Paragraph IV challenge, compared to 55% of drugs approved between 2000 and 2002); see also Hemphill, *An Aggregate Approach to Antitrust*, supra note 53, at 657–58 (noting increased intensity of antitrust enforcement and development of new strategies starting around 1997).

\(^5\) See Henry Grabowski et al., *Pharmaceutical Patent Challenges and Their Implications for Innovation and Generic Competition* fig.3 (Am. Econ. Ass’n, Working Paper, 2015), https://www.aeaweb.org/aea/2015conference/program/retrieve.php?pdfid=1203 [https://perma.cc/6A6X-TLPC]. In fact, as of 2006, the median number of years to a Paragraph IV challenge had dropped to a flat four years for both drugs with annual sales greater than $1 billion and those with sales less than $1 billion. *Id.* The FDA cannot accept a Paragraph IV ANDA until four years after the reference drug was initially approved for drugs with a theretofore unapproved active ingredient. See 21 U.S.C. § 355(j)(5)(F)(ii) (2012).

\(^5\) *Id.* Granted, the present value of money received closer to the decision date would be slightly higher than the present value of funds received later in the patent term. This is a small factor unlikely to undermine the logic used here. Further, as described in an earlier assumption, profits will not actually automatically drop to zero for both firms at the end of the 180-day exclusivity period. The first-filer will earn some profits even after the duopoly has been dismantled, giving the first-filer a reason to negotiate or desire an earlier entry date. *Id.* at 1585. Even if the certification is withdrawn or the first generic filer loses its infringement case, the six months of exclusivity are not available to any subsequent filer.

As part of the 2003 Medicare Modernization Act, Congress made changes to Hatch-Waxman that can cause a generic first filer to lose its 180 days of exclusivity if it enters into a pay-for-delay settlement.\footnote{21 U.S.C. § 355(j)(5)(D)(i)(I)(bb)(BB) (2012); 21 U.S.C. § 355(j)(5)(D)(i)(V) (2012).} Parties, however, have found a way to work around the new provisions. Five years after the 2003 amendment, monetary pay-for-delay settlements had instead increased, along with the rising popularity of Paragraph IV challenges.\footnote{Hemphill, An Aggregate Approach to Antitrust, supra note 53, at 649 tbl.2, 660.} The new provision did little to stem the tide.

Pharmaceutical companies have argued vigorously that pay-for-delay settlements are not anticompetitive, arguing that they can be understood as no more than devices by which the two parties respond to the uncertainty of patent infringement litigation.\footnote{Feldman, supra note 13, at 163.} Given the probabilistic nature of success in the lawsuit brought on by a Paragraph IV certification, the two parties calculate what they believe their relative position is in the litigation and then settle based on what they believe to be the expected value of bringing the litigation to its conclusion. Some argue further that such settlements are even procompetitive because the generic is typically allowed to enter the market before the last relevant patent expires.\footnote{Fed. Trade Comm’n v. Actavis, Inc., 133 S. Ct. 2223, 2227 (2013).} Thus, as a result of the settlement, the public will enjoy lower prices sooner than they would have—a result that would be consistent with the goals of Hatch-Waxman.

This argument suffers from two flaws. First, it ignores the fact that Paragraph IV litigation specifically questions the validity and applicability of the patent.\footnote{See id. at 2225; Hemphill, An Aggregate Approach to Antitrust, supra note 53, at 637–38.} If the patent is invalid or inapplicable to the drug, the brand-name company should have no exclusionary power.\footnote{See Actavis, Inc., 133 S. Ct. at 2225.} In other words, there is no such thing as “early entry” if the patent should not exist at all.\footnote{See generally Mark A. Lemley & Carl Shapiro, Probabilistic Patents, 2 J. Econ. Perspectives 75 (2005). Concurring, one of the authors of this piece has described a patent as creating “no more than an opportunity to bargain. It is an invitation to enter into a process of negotiating a definition of rights.” Feldman, supra note 13, at 2; see also Lear, Inc. v. Adkins, 395 U.S. 653, 670 (1969) (“A patent, in the last analysis, simply represents a legal conclusion reached by the Patent Office.”), cited in In re K–Dur Antitrust Litig., 686 F.3d 197, 214–15 (3d Cir. 2012); cf. Robin Feldman, Ending Patent Exceptionalism and Structuring the Rule of Reason: The Supreme Court Opens the Door for Both, 1 Minn. J.L. Sci. & Tech. 61 (2014).} Second, even if a patent is valid, it is not a license to engage in any and all activity,
2016] Drug Wars 513

no matter how anticompetitive. With any party that holds a legitimate monopoly position in the market, the antitrust laws place limits on what one can do with that monopoly power.67

After years of FTC action and cases that bounced around lower courts, the Supreme Court finally weighed in with its 2013 decision in FTC v. Actavis. The case involved a pay-for-delay settlement with the agreed upon entry date occurring prior to the patent’s expiration date.68 The Supreme Court ruled that the FTC’s case against a brand-name firm should have not been dismissed and that pay-for-delay settlements are open to antitrust scrutiny.69 Ruling that some pay-for-delay settlements may very well be anticompetitive, the Court declined to hold that reverse payment settlements are presumptively unlawful, however, preferring instead a rule of reason test.70

The rule of reason is a laborious standard that has been described by courts and commentators as difficult to meet and burdensome on both plaintiffs and the judicial system.71 The test involves complex economic analysis, requires extensive information about industries that may be difficult to obtain, and follows an amorphous set of standards that are difficult to pin down and establish.72 Thus, plaintiffs in an antitrust case try to avoid the rule of

---


68 It is worth noting that the settlement in Actavis was not a pure cash payment. Along with a payment to Actavis of approximately $19–30 million per year for nine years, Actavis also agreed to promote a drug sold by the brand-name company, among other considerations (two other generic companies—Par and Paddock, who were not first filers—also settled with the brand-name company). See Actavis, Inc., 133 S. Ct. at 2229. See infra Part IV for more information about settlements involving “side deals.”

69 Actavis, Inc., 133 S. Ct. at 2237.

70 Id.

71 See Robin Feldman, Defensive Leveraging in Antitrust, for a discussion of the rule of reason and the extensive criticism of it. 87 Geo. L.J. 2079, 2107–08 (1999) (citing the following sources: Jefferson Parish Hosp. Dist. No. 2 v. Hyde, 466 U.S. 2, 34 (1984) (O’Connor, J., concurring) (comparing the rule of reason to the odd form of per se rule applied in tying cases and describing both as requiring extensive and time-consuming economic analysis); Continental T.V., Inc. v. GTE Sylvania, 433 U.S. 36, 50 (1977) (describing rule of reason as complex and burdensome on litigants and the judicial system); Northern Pac. Ry. Co. v. United States, 356 U.S. 1, 5 (1958) (noting that rule of reason analysis requires complicated and prolonged economic investigation into the entire history of an industry and related industries); Robert Pitofsky, Antitrust in the Next 100 Years, 75 Cal. L. Rev. 817, 830, 830 n.42 (1987) (explaining that the court refused to apply rule of reason given the practical difficulties of the minute inquiry required into economic organization)).

72 See 7 PHILIP E. AREEDA, ANTITRUST LAW § 1502, at 371–72 (1986). The classic description of the rule of reason can be found in the seminal antitrust treatise by the late Philip Areeda. The plaintiff has the initial burden of establishing that the behavior restrains competition in a properly defined market, which includes delineating the relevant product and geographic markets. If the plaintiff meets this initial burden, the burden shifts to the defendant to show that its behavior serves legitimate objectives. If the defendant meets this burden, the
reason by framing the case to fit into one of a limited number of per se categories.

Although the rule of reason test traditionally has been the death knell for antitrust cases, the Supreme Court opened the door to serious antitrust consideration by suggesting that lower courts “structure” the rule of reason in these cases.73 Most important, the Court concluded that “a reverse payment, where large and unjustified, can bring with it the risk of significant anticompetitive effects.”74

In the aftermath of Actavis, courts and parties have taken the Supreme Court’s message to heart when it comes to pay-for-delay settlements in cash.75 In the FTC’s report on agreements between brand-name and generic companies in fiscal year 2014—the first full year after Actavis—the FTC found that the number of suspected pay-for-delay settlements dropped to twenty-one, compared to twenty-nine in fiscal year 2013 and the record-high of forty in 2012.76

Pay-for-delay agreements are also under fire outside of the United States. In early 2016, the United Kingdom’s Competition and Markets Authority announced total fines of £45 million against pharmaceutical companies engaging in pay-for-delay settlements.77 Between 2001 and 2004, a brand-name company had paid generics £50 million to delay entry of a popular antidepressant into the UK market.78

Looking again at the United States, two cases, in particular, also signal the beginning of the end for traditional delay games, leaving no doubt that plaintiff must then establish that the defendant could meet its objective using a less restrictive alternative. If the matter is still unresolved at this point, the court must weigh the harms and benefits of the restraint with the plaintiff shouldering the burden at this stage to show that the restraint is unreasonable on balance. See also Feldman, Defensive Leveraging in Antitrust, supra note 71, at 2107 n.143.

For analysis of the Actavis case, see generally Aaron Edlin et al., Activating Actavis, 28 ANTITRUST 16 (2013); Feldman, Ending Patent Exceptionalism and Structuring the Rule of Reason, supra note 65; Michael A. Carrier, Payment After Actavis, 100 IOWA L. REV. 7 (2014).

74 Actavis, Inc., 133 S. Ct. at 2237.
77 For further analysis of how courts have treated the Actavis decision, see generally Michele M. Kang, ANDA Reverse Payments and the Post-Actavis Landscape, 8 HASTINGS SCI. & TECH. L.J. 157 (2016).
76 See BUREAU OF COMPETITION, FED. TRADE COMM’N, AGREEMENTS FILED WITH THE FED. TRADE COMMISSION UNDER THE MEDICARE PRESCRIPTION DRUG, IMPROVEMENT, AND MODERNIZATION ACT OF 2003: OVERVIEW OF AGREEMENTS FILED IN FY 2014, at 4 exhibit 1, https://www.ftc.gov/system/files/documents/reports/agreements-filled-federal-trade-commission-under-medicare-prescription-drug-improvement/160113mmafy14rpt.pdf [http://perma.cc/6K2Y-NXM3]. Note that under the FTC’s definition of a pay-for-delay agreement, some of these agreements include side deals and “no-AG” clauses that will be discussed infra in Part IV.
78 The settlements included cash payments as well as supply and distribution agreements. See Jeff Overley, GSK Fined $54M Over UK ‘Pay-For-Delay’ Deals, LAW360 (Feb. 12, 2016, 11:03 AM), http://www.law360.com/ip/articles/758706 [https://perma.cc/FJ6Z-D2D8].
the guidance in *Actavis* is being used to heavily scrutinize these settlements. In the case of *In re Cipro*, the California Supreme Court applied *Actavis* to California’s own antitrust law, which follows certain aspects of federal law.\(^79\) The case concerned a pay-for-delay settlement regarding Bayer’s popular antibiotic, Cipro. Noting the probabilistic nature of patents and the uncertain nature of their validity, the court implemented a “structured rule of reason” test for scrutiny of reverse payment settlements, one falling somewhere between the notion that such settlements are per se illegal and the amorphous rule of reason.\(^80\) The test focuses on whether the value of that reverse payment exceeded litigation costs combined with the value of any other services the generic might agree to provide to the brand.\(^81\) Critically, the court held that in presenting any procompetitive arguments in favor of the settlement, the brand-name company may not include arguments that the patent is actually valid or that the settlement allowed pre-expiration entry.\(^82\)

Similarly, in the spring of 2015, Teva agreed to pay $512 million to settle a class action brought by direct purchasers of the company’s drug Provigil, a widely-used narcolepsy drug.\(^83\) The lawsuit had accused Teva of paying four different generic competitors—who had all filed their ANDA for Provigil on the same day—over $300 million to stay out of the market for six years.\(^84\) The settlement was the largest-ever for direct purchasers in a pay-for-delay case.

Just over a month after settling with direct purchasers, Teva agreed to settle similar antitrust claims with the FTC, bringing the total settlement to $1.2 billion, by far the largest settlement ever secured by the FTC.\(^85\) The

---

79. See generally *In re Cipro Cases I & II*, 348 P.3d 845 (Cal. 2015).
80. Id. at 862–63.
81. Id. at 865–67.
82. Id. at 870–71.
settlement came five days after an unfavorable ruling from a federal judge in the case.  

At the end of the day, however, Teva may still have profited handsomely from its behavior—although not nearly as handsomely as it had expected. Shortly after reaching the pay-for-delay settlement in 2006, one high level executive commented that, “[w]e were able to get six more years of patent protection. That’s $4 billion in sales that no one expected.” Even considering the FTC’s lower end estimate of $3.5 billion in profit from the delay, the company was still left with $2.3 billion after settling with the class action plaintiffs and the FTC.

IV. “Generation 2.0”: Pay-For-Delay Takes New, Complicated Forms

A. Already Steps Ahead of Actavis

Although Actavis dealt a severe blow to pay-for-delay settlements, it came years too late. Drug manufacturers had long moved on to other forms of settlement, specifically, combining delay provisions with other agreements meant to obscure the fact that the generic firm is still receiving large considerations in return for delay. In these “Generation 2.0” games, the reverse payment is still very much alive—it is just not so clearly denoted by dollar signs.

The first Generation 2.0 settlement is generally understood to be a 1997 agreement to delay entry of K–Dur, a drug treating potassium deficiencies. In the agreement, the first generic filer agreed to delay entering the market for approximately four years. What differed in this first Generation 2.0 agreement was what the brand-name drug company added to the agreement. The brand-name drug agreed to buy licenses to multiple medications from the generic—in particular, a cholesterol drug known as Niacor-SR, which the generic had developed. The brand-name drug company paid the generic $60 million and agreed to pay royalties on Niacor-SR, depending on its sales of the product. The two parties quickly abandoned their plans to make Niacor-SR, leaving the $60 million “license” payment intact.
The *K–Dur* case presents the archetypical form of a classic Generation 2.0 settlement. As part of a generic delay agreement, the two parties agree to provide services for each other, frequently referred to as “side deals” and often related to other drugs in one of the firms’ portfolio. Cash is often still exchanged, but it is disguised as a payment for the other services mentioned in the agreement. As detailed below, these services can include: promises on the part of the generic to promote or market the brand-name drug (“co-promote deals”); licensing deals allowing the brand-name drug company or the generic to manufacture the other party’s drug; similar “authorized generic” agreements permitting the generic to manufacture and/or sell the brand-name formulation as a generic without ANDA approval, with profit-sharing or royalty deals attached; agreements to share research and development duties on a future project; deals to supply the brand-name company with raw materials for manufacturing; and more. 

In most cases, the result is that the generic is “overpaid” for the services it supposedly furnishes to the brand—with the difference between the market value and the actual payment being the cash consideration for the delay. In the alternative, the generic may “underpay” for something it receives from the brand-name drug company, such as the right to make other drugs from the brand-name drug company’s portfolio. 

A particularly questionable part of these side deals is that the services promised are often beyond the generic’s capability. For example, a generic company generally does little marketing and relies on the fact that pharmacists will automatically substitute a generic drug when filling a prescription listing the brand-name drug. How, then, could a generic manufacturer offer marketing and promotion services that a brand-name company would find desirable? And, as Hemphill notes, it is rarely obvious that a generic firm would be the most effective manufacturing and supply partner for a large brand-name company. The side deals are hollow promises that may or may not ever be fulfilled. Rather, they may function purely as a facade for the pay-for-delay deal that lies beneath the language of the settlement. Teasing out these pay-for-delay deals, however, can be quite difficult.

**B. In re Lipitor: Everything But the Kitchen Sink**

While the Court of Appeals for the Third Circuit appeared to easily see through the intent of the two parties’ side deal in *K–Dur*, getting to the bot-

---

92 Recall that *Actavis* also had elements of a Generation 2.0 settlement (e.g. side deals, installment payments). We associate *Actavis* with Generation 1.0 in this Article given that the *Actavis* argument has been successfully applied only to cash deals as of now.


94 See id. at 663–64. See generally Carrier, *Payment After Actavis*, supra note 73.


96 See id. at 668.
tom of a settlement is not always so easy. Clarity is particularly difficult to achieve when companies settle multiple Hatch-Waxman cases at once, distributing the payoffs in a way that quickly becomes quite complex.

Consider the case of In re Lipitor, which involved one of the most tangled sets of agreements in all of generic delay. Lipitor, a statin used to lower cholesterol, is widely known as the best-selling drug in history, with over $125 billion in sales between 1996 and eventual generic entry in late 2011. It is no surprise that Lipitor’s manufacturer, Pfizer, went to unprecedented lengths to protect the monopoly on its ultra-blockbuster. A protracted six-year battle between Pfizer, and the first generic filer, Ranbaxy, led to a settlement including delay of generic Lipitor. Scrutiny of this settlement then led to multiple class action lawsuits.

Together, the resulting litigation implicated issues including, but not limited to: sham litigation, sham patent obtainment through data falsification, Orange Book listings (and patents not listed in the Orange Book), sham citizen petitions, multiple and staggered suits, multiple settlements, and even ANDA approval delay on the part of Ranbaxy through a delay in moving the site of generic manufacture to an FDA-approved facility. For the sake of clarity, this discussion will only focus on the terms of the eventual settlement between Pfizer and the first generic filer.

In the 2008 settlement, the generic company agreed to delay release of generic Lipitor until late 2011. In return, Pfizer gave the generic the right to market generic Lipitor in eleven international markets. Pfizer also re-

---


101 See End-Payer Amended Complaint, supra note 100 (breaking down all the alleged methods of delay in the case); see also In re Lipitor Antitrust Litig., No. 3:12-cv-2389, 2013 WL 4780496, at *12 (D.N.J. Sept. 5, 2013) (granting in part and denying in part motion to dismiss class action claims and referencing the claims regarding Ranbaxy’s purposeful negligence of data integrity and manufacturing practices); see also Complaint and Jury Demand, Meijer, Inc. v. Ranbaxy, Inc., No. 1:15-cv-11828, 2015 WL 2219184 (D. Mass. May 12, 2015) (arguing manufacturing problems have been widespread for Ranbaxy and the result of their haste to put in ANDAs and lock in 180-day exclusivity).

102 In re Lipitor, 2013 WL 4780496, at *12. Complaint alleged this aspect of the settlement created an ANDA bottleneck that blocked the approval of subsequent ANDAs. End-Payer Amended Complaint, supra note 100, at paras. 373–92.
solved other litigation with the generic involving the drugs Caduet and Accupril.\footnote{In re Lipitor, 46 F. Supp. 3d at 532–33. Also dismissed was a process suit over the same two patents asserted against Ranbaxy over Lipitor. See End-Payer Amended Complaint, supra note 100, at paras. 270–82.}

In a class action complaint, end payors alleged that this settlement represented an unlawful reverse payment.\footnote{End-Payer Amended Complaint, supra note 100, at paras. 393–95.} Their argument was as follows: Pfizer knew it was unlikely to win its remaining challenges to the launch of generic Lipitor.\footnote{A district court had already enjoined approval of Ranbaxy’s ANDA until March 2010 by upholding one of Pfizer’s patents. In re Lipitor, 2013 WL 4780496, at *7; FELDMAN, supra note 13, at 162. Pfizer’s infringement claim on its second patent (the subject of much controversy) was not upheld. It then turned to reissue proceedings for that second patent as well as a citizen petition to attempt to delay entry. In re Lipitor, 2013 WL 4780496, at *6–10. Together, complainants allege the only thing preventing generic entry in March 2010 was a patent reissue application that had a “real risk” of being “denied” and a citizen petition that was still pending: End-Payer Amended Complaint, supra note 100, at paras. 243, 266.} However, it had a very strong case against the generic regarding the other drug, Accupril.\footnote{In a bizarre series of events, Ranbaxy (partnering with Teva) launched a generic version of Accupril at-risk in December 2004—meaning that it launched before a judgment was made as to the validity or invalidity of Pfizer’s patents and thus presenting the possibility that it could face substantial damages if the patents were later judged to be valid and infringed. In re Lipitor, 46 F. Supp. 3d at 532. It did so despite Pfizer having already secured summary judgment that an earlier ANDA applicant had infringed patents related to Accupril. Id. at 531. Pfizer’s sales of Accupril dropped from $534 million in 2004 to just $71 million after generic launch. End-Payer Amended Complaint, supra note 100, at para. 296. In light of the other Accupril decision over the first ANDA, a court granted a preliminary injunction on sales of generic Accupril, and Pfizer appeared to be very confident that Ranbaxy would be found liable for hundreds of millions of dollars in damages. In fact, they requested that treble damages be awarded under the theory that Ranbaxy willfully infringed the Accupril patents. End-Payer Amended Complaint, supra note 100, at paras. 310–11. Yet, as described infra, Pfizer was apparently willing to settle the case for only $1 million.} In fact, it was widely believed that the suit over Accupril could have easily been worth hundreds of millions of dollars in damages.\footnote{End-Payer Amended Complaint, supra note 100, at paras. 314–18.} In exchange for letting the generic go on the Accupril litigation (for a seemingly trivial $1 million paid by the generic), it was able to secure delay in the launch of generic Lipitor. Thus, while the Lipitor settlement involved no cash exchange, and the Accupril settlement involved only $1 million, complainants alleged that Pfizer’s stunning and unexpected act of generosity regarding Accupril was actually a “massive [reverse] payment worth hundreds of millions of dollars to [the generic].”\footnote{Id. at para. 314.} In other words, Pfizer paid for the delay by giving up another case worth hundreds of millions of dollars.

To put an obfuscating bow around the entire deal, Pfizer allegedly initiated a separate sham lawsuit in order to create the illusion of a lawful settlement. At the time of the settlement, Pfizer had no pending litigation against
the generic regarding Lipitor. However, if the company’s aim was to get a settlement that included the delay of Lipitor, there had to be a pending Lipitor case to settle. Thus, Pfizer sued the generic over infringement of two process patents not listed in the Orange Book for Lipitor—two patents for which a court had already said Pfizer had no standing to assert against the generic. Three months later, Pfizer and the generic company reached their “agreement” to settle the newly initiated litigation. With all terms considered, some industry estimates pegged the value of the settlement at more than $1.5 billion for the generic. How much of that figure, however, was payment for keeping Lipitor off the market?

In 2014, this question came before the District Court for the District of New Jersey. The court dismissed direct purchaser class actions for failure to state a claim because the plaintiffs were unable to provide “a reliable estimate” of the monetary value of the reverse payment. It can indeed be difficult to tease out the value of a reverse payment, making these types of complex settlements an attractive option for pharmaceutical companies. First, the plaintiff in this case would need to determine the market value of each piece of the settlement, including the value to the generic of: ending the (supposedly sham) litigation between Pfizer and the generic; earning the rights to market generic Lipitor in international markets; ending the Accupril case; and ending the Caduet litigation. Next, the plaintiff would have to show how much the generic actually “paid” for these pieces of the settlement and then prove that the gap between the market value and the actual value of the settlement represents the reverse payment from Pfizer to the generic to secure Lipitor delay. This presents an enormous hurdle for a plaintiff to clear, and it has led to the dismissal of other related Lipitor class actions.

109 But it was waiting on the results of a pending citizen petition and an application for reissuance of one of its Lipitor patents. Plus, Ranbaxy was already enjoined from receiving ANDA approval and entering the market until 2010. In re Lipitor, 2013 WL 4780496, at *7.
110 End-Payer Amended Complaint, supra note 100, at paras. 270–82. One reason that the patents could not be legitimately asserted is that they were not “Hatch-Waxman” patents listed in the Orange Book. Recall that an ANDA filing is only artificially a patent infringement action against the patents listed in the Orange Book. Since the patents were not listed, no infringement real or artificial could have taken place. Thus, there was no “justiciable case or controversy” since the “mere threat of [future] litigation” could not support the case for Pfizer’s preliminary injunction. In re Lipitor, 2013 WL 4780496, at *10; Hemphill, An Aggregate Approach to Antitrust, supra note 53, at 639 n. 39.
111 End-Payer Amended Complaint, supra note 100, at para. 279.
112 Id. at para. 279.
113 In re Lipitor, 46 F. Supp. 3d at 550.
114 So little about the Caduet litigation was mentioned in the end-payor complaint that the district court cited it as a reason for dismissing the case, since the complaint failed to address in any way how settling the Caduet litigation factored into the global scope of the settlement. In re Lipitor, 46 F. Supp. 3d at 523, 533, 548.
Drug Wars

C. Contract Clauses and King Drug

Lipitor was not the only set of cases dismissed for an apparent failure to define the scope of a reverse payment. In a few other cases, courts also have not been easily persuaded that side deals constitute a reverse payment, particularly in the context of renewed debate after Actavis over the definition of what constitutes a “large, unjustified” payment.116 Other Generation 2.0 settlements, however, do not hinge on actual service contracts or settling multiple cases; rather, the contract clauses themselves can serve as indirect payments and bottlenecks to prevent later generics from entering.

One popular contract item is an “acceleration clause” (also known as a “coordination clause”). An acceleration clause stipulates that the generic company, which has agreed to delay entry, may immediately enter the market if another generic is able to jump the queue and get into the market before the first-filer’s 180-day exclusivity period ends (or even before it begins). This can happen through a variety of complex strategies, described below, that later-filing generics may be able to use in certain circumstances.117 With an acceleration clause, the first-filer is not locked into its agreed entry date if another generic manufacturer is able to break through the exclusivity period fence.

The true benefit of an acceleration clause, however, is not the reassurance it provides to the delaying generic entrant. Rather, it is the disincentive the clause creates for other prospective generics. After an acceleration clause is put in place, any generic looking to find a way onto the market does so with the knowledge that, if they are successful, they will immediately face generic competition from the first-filer. Thus, entrance is less attractive, especially given the legal battle necessary to employ the strategies that will secure an earlier place on the market for a later-filing generic. In turn, the chance that the first-filer will be able to launch as the only generic—with the 180-day exclusivity period intact—is increased. Also improved is the chance that the brand-name drug company will be able to enjoy the full delay period as the monopoly seller, as well as the full 180-day duopoly period when the


117 See discussion infra Section V.E for more details on some of these strategies.
first-filer finally enters. In essence, the brand-name firm pays the generic by reducing the risk of competition in exchange for a commitment to delay.\textsuperscript{118}

Of particular note among the contract clauses are ones this Article labels “boy scout clauses”—that is, clauses in which the brand-name company promises good behavior but does so in a way that has anticompetitive effects. Consider the issue of authorized generics. Brand-name companies often introduce generic versions of their own drugs, at a lower, unbranded price tier, to compete against the incoming first filer. Given that the brand-name company already has FDA approval, it is not subject to generic approval processes, and, therefore, its own generic version is not restricted from entering the market during the first filer’s 180-day exclusivity period. This allows the brand-name company to hold onto a portion of the profits that would otherwise go to the first generic filer, and it reduces the incentive for entering generics. Early on, commentators expressed concern about the potential anticompetitive effects of the practice and whether it undermines the Hatch-Waxman incentive structure.\textsuperscript{119}

Against this backdrop, some brand-name companies have included a clause in their pay-for-delay settlements known as a “no-authorized-generic agreement” (‘no-AG agreement’). In a no-AG agreement, a brand-name firm agrees not to launch a generic form of its drug until the first-filer’s 180-day exclusivity period has expired. In return, the potential generic manufacturer delays entry. The brand-name company, of course, retains the right to continue selling the more expensive branded version of the drug through both the generic delay period and the 180 days of exclusivity.

What is so clever about this form of agreement is the following: having received criticism for its behavior of creating authorized generics, the brand-name company now stands up and faithfully swears not to engage in the practice. What matters, however, is the context. The brand-name company is agreeing to shun this practice in exchange for an agreement that the generic will delay its entry. The value of forgoing authorized generic entry becomes part of the payment for delay. In other words, having developed inappropriate behaviors, the brand-name company can now agree to forgo them, using the value of what would have been ill-gotten gains to pay the generic. All of this is wrapped in the guise of a boy-scout-like promise to be on good be-

\textsuperscript{118} A recent complaint alleges that a brand-name firm included acceleration clauses in delay agreements with three different ANDA filers (who all filed first on the same day) in order to reduce the incentive for Teva to launch a generic, and using a strategy in which Teva argued that its generic would not be used for patent-protected indications of Actos. \textit{Cf.} Consolidated Class Action Complaint and Jury Demand, \textit{In re Actos Direct Purchaser Antitrust Litig.}, No. 1:15-cv-03278, 2015 WL 4600605 (S.D.N.Y. June 4, 2015).

\textsuperscript{119} For a detailed analysis of the effects of authorized generics, notably concluding that authorized generics are generally procompetitive and price-reducing, but may cause harm when coupled with no-authorized-generic agreements, see generally \textit{Fed. Trade Comm’n, Authorized Generic Drugs: Short-Term Effects and Long-Term Impact} (2011), http://www.ftc.gov/os/2011/08/2011genericdrugreport.pdf [https://perma.cc/64U3-HL7P]. The FTC also noted limited cases where the anticipated presence of authorized generic competition could have been a disincentive for potential generics.
2016] Drug Wars 523

havior. It is a little like the schoolyard bully who agrees to stop hitting the younger kids in exchange for their lunch money. When hauled into the principal’s office, he says in great seriousness, “but didn’t you want me to stop hitting them?” A later version of a boy-scout clause appears in the Generation 3.0 tactics in the form of no-product-hopping agreements.

A very recent case involving a no-AG agreement is King Drug, which led to a landmark opinion in June 2015 from the Court of Appeals of the Third Circuit. The Third Circuit was among the first to look skeptically at side deals involving cash in K-Dur; in King Drug, that skepticism was extended to non-cash reverse payments such as no-AG agreements. The court found that such payments are not immune to Actavis-style rule of reason scrutiny and that direct purchasers suing over the settlement in question had sufficiently pleaded their Sherman Act claims.

King Drug arose out of a settlement between GlaxoSmithKline and the first generic filer over Glaxo’s brand drug Lamictal, an anticonvulsant drug used to treat epilepsy and bipolar disorder. In the Paragraph IV litigation, the district judge invalidated the primary claim in the Lamictal patent. One month later, the parties agreed to settle in what was, by that point, a case that the brand drug company was likely to lose.

No cash was exchanged as part of the settlement. Instead, Glaxo allowed the generic to enter the $50 million market for chewable Lamictal thirty-seven months before the patent expired; however, the settlement did not permit entry into the more lucrative $2 billion Lamictal tablet market until one day before the expiration of Glaxo’s exclusivity. Employing a no-AG agreement, Glaxo also agreed that it would not introduce its own generic version of Lamictal tablets until after the generic’s 180-day exclusivity period. Direct purchasers challenged this settlement in a class action, alleging that the no-authorized-generic agreement was an anticompetitive reverse payment.

In June 2015, the Third Circuit agreed that a no-AG agreement may represent an “unusual, unexplained reverse transfer of considerable value” under Actavis, allowing the antitrust claims to continue. The reasoning

---

120 In this case, however, the lunch money is coming from consumers, who pay in the form of higher prices.
121 See infra Section V.B.
123 King Drug Co. of Florence, Inc. v. Smithkline Beecham Corp., 791 F.3d 388 (3d Cir. 2015).
124 Id. at 409.
125 Id. at 397.
126 Id. at 409–10.
127 Id. at 397.
128 Id. at 394. The early entry to the chewable market was largely ignored in the opinion, mainly because the size of the market is magnitudes smaller than the tablet market. Even if this agreement were slightly competitive, the court decided “plaintiffs have sufficiently alleged
applied was similar to that of Actavis, but the court also explained the ways in which a non-cash payment such as this could have considerable value for both parties. In particular, if the court had reached a final judgment that the generic did not infringe the patent—which seemed likely at this point—the generic would have been able to enter the tablet market long before the settlement entry date, bringing down the price at an earlier time while enjoying its 180 days of exclusivity. In exchange for dodging this bullet, the brand-name company agreed that when the 180-day exclusivity finally arose, it would not introduce an authorized generic version. It was, essentially, a promise not to compete.130

This “generic monopoly,” as the court describes it, can be worth hundreds of millions of dollars more than a generic market featuring both the first-filing generic and the authorized generic.131 As the court noted, authorized generics may cut first-filer revenues by “40 to 52 percent” during the 180 days of exclusivity.132

In short, Generation 2.0 has featured lucrative side deals between the brand-name drug company and the generic. These allowed the companies to camouflage the nature of the transfer by arguing that no “pay” had been received for the “delay” and that the agreements were simply a settlement of litigation expectations and risk.

V. “GENERATION 3.0”: PAY-FOR-DELAY REPLACED BY ACTIVE OBSTRUCTION OF GENERICS

A. General Description and the Economics at Play

Actavis and Cipro combined to presumptively deliver a knockout punch to rudimentary cash pay-for-delay deals. In the same vein, King Drug landed a major post-Actavis blow to “Generation 2.0” deals, where the trail of the large, unexpected payments is hidden behind multiple settlements combining layers of superfluous deals with valuable contract clauses. With their ability to enter into pay-for-delay deals severely diminished, brand-name drug companies are turning to new strategies that actively obstruct generics from entering the market. The point of obstruction can come at different stages of

that [these aspects] . . . were outweighed by the anticompetitive harm of the no-AG agreement.” Id. at 410.
129 Id. at 405.
130 Id. at 406–07, 406 n.27.
131 Id. at 405.
132 Id. at 404 n.21 (citing Fed. Trade Comm’n, supra note 119, at iii). The Court used the term “generic duopoly” to describe when the brand-name drug company and the first generic are both in the market with generic versions. It should be noted, however, that this market structure is different from what economists generally refer to as a duopoly, which occurs when the original drug maker is selling its own branded drug and the first generic is selling a generic version. In contrast, the court’s “generic duopoly” market may feature three versions of the drug on the market—the brand-name drug and two generic versions—one made by the original drug maker and one made by the first filing generic.
generic development: before an ANDA is submitted, during the ANDA approval process, after a generic drug has been approved for marketing, or even once the generic has managed to enter the market.

As this Part will explain, the mechanisms of obstruction are varied and complex, but most use strategic behavior in the generic substitution system or in FDA regulatory processes to attempt a delay. In cases of what is known as “product hopping,” for example, the brand-name drug company takes advantage of its market power to shift pharmacists, doctors, and consumers to new versions of drugs before a generic for the “old” version is able to reach the market.133 A second mechanism uses FDA guidelines meant to ensure the safe use of potentially dangerous or potent drugs to prevent potential generic manufacturers from accessing drug samples necessary to test for bioequivalence. A third uses a process available to the public to raise concerns about pharmaceuticals in order to bring about a FDA review of the petition during which ANDA approval will be delayed—knowing full well that the FDA is likely to take months (or longer) to review even entirely groundless claims.

The new obstruction strategies may result in anywhere from a few months up to a couple years of delay, in contrast to the multiple years of delay that reverse payment agreements can create.134 Obstruction strategies also are unlikely to be successful beyond the months of delay garnered by filing an FDA petition or refusing to deal drug samples. Many of the attempts are likely to be rejected by the FDA. Nevertheless, even a rejected or dismissed attempt at obstruction can be worth hundreds of millions of dollars. Pay-for-delay can be extremely valuable—if a branded drug has $1 billion in annual U.S. sales, an agreement with the generic to delay entry for three to four years is worth billions to the brand-name company—even when factoring in the cost of paying the generic to delay.135 If those settlements are not available, however, any form of delay is valuable if the costs and risks are low.

Consider the example of a citizen petition asking the FDA to delay approval for a generic.136 The cost of filing a citizen petition is trivial com-

---


134 There are, of course, exceptions and edge cases where “Generation 3.0” strategies have been successful in achieving several years of generic entry delay. Product hopping, in particular, has been an effective mechanism for longer-tern delay.

135 See Part III for more discussion about the economics behind pay-for-delay. Further, the estimate above of the value of pay-for-delay is not unreasonable. Of the top 100 drugs in the United States by revenue in 2013, the median drug had sales over $1 billion. U.S. Pharmaceutical Sales-2013, DRUGS.COM, http://www.drugs.com/stats/top100/2013/sales [https://perma.cc/3Q4Z-TVZT] (last updated Feb. 2014) (reporting sales data for Lovaza and Gilenya, the 50th and 51st best-selling drugs, respectively). If the brand-name manufacturer is able to broker a delay of three years for $500 million, the branded manufacturer gets $2.5 billion out of the deal, assuming that branded sales are negligible after generic introduction.

136 The details of the citizen petition process will be explained infra at Section V.D.
pared to the expected value of the benefits, even if success is unlikely.\footnote{See Darren S. Tucker, \textit{FDA Citizen Petition: A New Means of Delaying Generic Entry?}, 20 \textbf{ANTITRUST HEALTH CARE CHRON.} 10, 11 (2006) (citing Comment of the Staff of the Bureau of Competition & the Office of Policy Planning of the Fed. Trade Comm’n Before the Food & Drug Admin. In the Matter of Citizen Petitions; Actions That Can Be Requested by Petition; Denials, Withdrawals, and Referrals for Other Administrative Action, FDA Docket No. 99N-2497, at *4, 6–7 (Mar. 2, 2000), https://www.ftc.gov/sites/default/files/documents/advocacy_documents/ftc-stuff-comment-food-and-drug-administration-concerning-citizen-petitions/v000005.pdf [https://perma.cc/AP3K-LVM4]).} Although recent FDA guidance requires that citizen petitions with the potential to affect generic approval must be considered within 150 days,\footnote{U.S. FOOD & DRUG ADMIN., GUIDANCE FOR INDUSTRY: CITIZEN PETITIONS AND PETITIONS FOR STAY OF ACTION SUBJECT TO SECTION 505(Q) OF THE FEDERAL FOOD, DRUG AND COSMETIC ACT 3 (Nov. 2014), http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm079353.pdf [https://perma.cc/ZEX4-QLLG] (discussing Section 505(q)(1)(F)).} those approximately five months of delay could be worth hundreds of millions of dollars in additional monopoly revenues as the generic sits on the sideline waiting for approval.\footnote{This calculation assumes the same $1 billion in annual sales for a top 100 drug used in note 135.} It is not billions, but it will do. In short, the new strategies might impact a shorter term with lower rewards, but their minimal cost makes them worth a try when some not entirely baseless claim or objection can be produced.\footnote{Granted, the cost of these strategies could climb much higher than $25,000 as companies begin to face antitrust litigation for their actions and must expend millions on legal fees after the fact. Until these cases are regularly ending in settlements worth billions to the plaintiffs, however, these “games” are still valuable for brand-name drug companies.}

In addition, some of these strategies could conceivably approach the high-flying numbers of pay-for-delay settlements. Take the example of \textit{In re Flonase Antitrust Litigation}.\footnote{In re Flonase Antitrust Litig., 951 F. Supp. 2d 739 (E.D. Pa. 2013) (approving direct purchaser settlement); \textit{In re Flonase Antitrust Litig.}, 291 F.R.D. 93 (E.D. Pa. 2013) (approving indirect purchaser settlement). Further, the value of this strategy is higher considering the possibility that the petition or request of the brand might actually be accepted. For example, some have found that the FDA granted about twenty percent of the citizen petitions filed by brands against generics between 2008 and 2010. Michael A. Carrier & Daryl Wander, \textit{Citizen Petitions: An Empirical Study}, 34 \textbf{CARDOZO L. REV.} 249, 276 (2012), http://cardozolawreview.com/content/34-1/CARRIER.34.1.pdf [https://perma.cc/J8ND-2FGC].} At its peak, Flonase, a steroid nasal spray for allergy treatment, reached $1.3 billion a year in sales.\footnote{Tracy Staton, \textit{GSK Reaches $150M Deal in Flonase Antitrust Case}, FIERCEPHARMA (Dec. 20, 2012), http://www.fiercepharma.com/story/gsk-reaches-150m-deal-flonase-antitrust-case/2012-12-20 [https://perma.cc/9QZX-QD3].} Through a complicated series of citizen petitions, GlaxoSmithKline was able to stave off generic entry for twenty-three months.\footnote{See Seth C. Silber, Jonathan Lutinski & Rachel Taylor, \textit{Abuse of the FDA Citizen Petition Process: Ripe for Antitrust Challenge?}, \textbf{ANTITRUST HEALTH CARE CHRON.}, Jan. 2012, at 26, 33–35, https://www.wogr.com/PDFSearch/silber0112.pdf [https://perma.cc/78J8-BFQP] (describing the delay mechanisms used by GSK).} Thus, the delay achieved through citizen petitions was worth approximately $2.5 billion, assuming it maintained the peak $1.3 billion in sales per year. In two class action lawsuits that were later filed against Glaxo, the company settled for a total of...
Drug Wars

$185 million. Thus, even with the settlement, the delay may have been worth $2.3 billion.

This Part continues with a discussion of the Generation 3.0 delay strategies that make up the toolbox for a branded pharmaceutical manufacturer, starting with perhaps the most well-known: product hopping and evergreening.

B. Product Hopping and Evergreening

Commentators have written for some time on the phenomenon known as evergreening, in which a company tries to refresh its market monopoly by making slight modifications to the delivery mechanism, dosage, or other characteristics to make the drug eligible for additional exclusivity or patents. As described above, Generation 3.0 strategies involve active obstruction of generic entities, rather than side deals. One of the first Generation 3.0 strategies involves a variant of evergreening called “product hopping.”

The following steps make up a product hop. First, the brand-name drug company makes a small change to its existing drug, right as its patents or regulatory exclusivities are about to expire, and introduces the new formulation as an entirely new drug. This new form is generally protected by new patents corresponding to the minor changes. The move forces a market shift away from the old drug—just as it is approaching its patent cliff.

The brand-name drug company brings about the market shift in a number of ways. Notably, the brand-name company usually undertakes a significant promotion and advertising campaign to herald the benefits of the “new” medication and push doctors to write prescriptions for the new drug. This strategy obstructs generic substitution in different ways, depending on the nature of the product hop. When the product hop involves a shift to an entirely new drug (e.g. a shift from Prilosec to Nexium in the market for heartburn relief and other stomach acid-related conditions, as described below), convincing doctors to prescribe the new drug prevents generic substitution simply because there is no generic equivalent.

Alternatively, in the case in which the product hop involves a switch to a new form of the drug (e.g. a shift from Suboxone tablets to Suboxone film


strips, as described below, in Section C), pharmaceutical representatives often ask physicians to append a note to their prescriptions asking the pharmacist to “Dispense as Written.”\textsuperscript{146} This prevents pharmacists from dispensing the generic version of the old form of the drug since the doctor has specifically requested the new form—a form for which there is no generic substitute.

Meanwhile, the brand-name company provides a monetary incentive to drug payors—including insurers, managed care organizations, and pharmaceutical benefit managers—to catalyze the product hop.\textsuperscript{147} The new drug is often introduced with significant rebates and discounts to insurers, causing these insurers to prefer the use of the new drug over the old form in the short-term.\textsuperscript{148} An insurer may even place the new drug in a preferred position in its formulary of drugs covered for patients—meaning that the patient co-pay for the new drug is likely to be lower compared to that of the old form. Thus, pressure for doctors to prescribe the new drug comes from all sides: from pharmaceutical reps preaching the benefits of the product hop, from patients wishing to minimize their co-pay, from insurers who have a short-term financial incentive to prefer the new drug, and from pharmacists who recognize the preferential place of the new drug on formularies and ask doctors to change prescriptions to the new drug even when the old form is prescribed.\textsuperscript{149}

\textsuperscript{146} See Genentech’s “Preserve Your Branded Choice” website for CellCept (a drug that prevents organ rejection after transplants), which heavily encourages healthcare professionals to write “Dispense as Written” on prescriptions so branded CellCept is dispensed. The website even includes a separate PDF file for all fifty states, the District of Columbia, Guam, and Puerto Rico, with specific information about the “Dispense as Written” guidelines in each jurisdiction. \textit{Preserve Your Branded Choice, CellCept}, http://www.cellcept.com/hcp/prescribing-branded-cellcept [https://perma.cc/ATX8-PEA9].

\textsuperscript{147} For some further discussion of this issue, see Shadowen, Leffler & Lukens, supra note 145, at 17–21.

\textsuperscript{148} Note that these rebates are really only valuable to the insurer when you compare the price of the brand’s “old drug” to the rebated/discounted price of the new drug. The cheapest option for the insurer would be to pay for a generic version of the old drug at a price cheaper than even a discounted version of a patent-protected new formulation. Further, rebates and discounts are likely to disappear or diminish once the product hop is sufficiently completed.

\textsuperscript{149} Consumers often receive financial incentives on top of differential co-pays. Many pharmaceutical companies provide co-pay “coupons” or “rebates” to patients. These incentives discount the patient’s out-of-pocket costs for drugs at the point of sale, perhaps influencing the patient to purchase expensive drugs while shifting all cost (and risk) onto insurers. The economic implications of these coupons are an ongoing subject of debate in pharmaceutical pricing. Massachusetts was the only state to have banned these coupons until its law was repealed (for drugs without generic equivalents) in 2012, and federal health insurance (e.g. Medicare, Medicaid, veterans’ benefits) users are ineligible for coupon benefits under anti-kickback laws. \textit{See} David Schultz, \textit{Drug Coupons: A Good Deal For The Patient, But Not The Insurer, KAISER HEALTH NEWS} (Oct. 1, 2012), http://khn.org/news/drug-coupons/ [https://perma.cc/D6Y3-SMPC] (noting laws preventing those on federal health insurance from using coupons and detailing the debate over co-pay rebates); Karen Weintraub, \textit{Mass., 50th State, Now Allows Drug Coupons: What You Need To Know}, WBUR (July 16, 2012, 9:40 AM), http://commonhealth.wbur.org/2012/07/drug-coupons-massachusetts [https://perma.cc/3AFV-P8KF] (covering repeal of Massachusetts’s drug coupon law). As of February 2016, CellCept, the drug described in note 146, provided a co-pay card to consumers, along with the push for
To complete the product hop, brand-name companies will often discontinue the previous version of the drug, closing distribution channels and sometimes even buying back all remaining inventory of the drug. In some cases, the original drug is eventually removed or excluded from the insurance formularies or national databases used to determine generic equivalence, such as First Databank MedKnowledge, formerly known as (and still often referred to as) the National Drug Data File.

When the original branded drug is excluded from formularies, use of an equivalent generic generally comes to a full halt. Substitution cannot take place because there is no longer a brand-name drug for the generic on the market. Even if a doctor were to write a prescription specifically for the generic instead of the new branded drug, most insurance companies will consider the generic drug to be a “branded” drug for co-pay and reimbursement purposes since it is the only drug on the market, which shifts more costs onto the consumer and discourages use of the drug.

In sum, the result is that a generic that was supposed to create competition for the original brand-name drug can no longer gain a foothold in the market. In a variant on this strategy, AstraZeneca switched the market from its original drug Prilosec to Nexium by moving Prilosec from a prescription medication to an over-the-counter drug, and then shifting the prescription market to a newly patented Nexium. Commentators have argued that Nexium is little different from its predecessor drug.

The strategy has been enormously successful. Before patent expiration, Prilosec was the country’s number one selling drug with $6 billion per year in sales. In 2013, twelve years after Nexium launched, Nexium was the number two selling drug with just under $6 billion in sales, $2.5 billion of doctors to prescribe the branded medication. CellCept CoPay Card, CellCept, http://www.cellcept.com/hcp/patient-financial-resources/cellcept-copay-card [https://perma.cc/93H3-S2CA].

See Feldman, supra note 13, at 175. In at least one instance, a pharmaceutical company “managed to persuade the FDA to withdraw its license” for an original branded drug right as generic competition was about to be permitted. Lars Noah, Product Hopping 2.0: Getting the FDA to Yank Your Original License Beats Stacking Patents, 19 Marq. Intell. Prop. L. Rev. 161, 165 (2015).

See Teva Pharm. USA, Inc. v. Abbott Lab., 580 F. Supp. 2d 345, 355 (D. Del. 2008) (featuring the case of TriCor, in which the brand-name manufacturer recoded earlier versions of TriCor as “obsolete” in the NDDF, allegedly blocking some substitution); see also Carrier, A Real-World Analysis of Pharmaceutical Settlements, supra note 2, at 1019–20 (discussing TriCor and the National Drug Data File).

You might remember the omnipresent commercials featuring comedian “Larry the Cable Guy” trumpeting the news that Prilosec was available over-the-counter.

See Feldman, supra note 13, at 171. Prescription Prilosec was not completely discontinued, but the move to over-the-counter availability created a product hop because insurers excluded Prilosec from their formularies once it became available without a prescription.

which is paid by the government and its beneficiaries under Medicare Part D.\textsuperscript{155}

Other recent cases have even more alarming fact patterns. Consider Asacol, a drug used for the treatment of chronic ulcerative colitis. As the expiration of the Asacol patents approached and at least two generic companies planned to enter upon expiration, the brand-name manufacturer undertook a number of actions to extend its monopoly franchise.\textsuperscript{156} First, it developed a higher-dose, extended-release version of the Asacol tablet.\textsuperscript{157} The new version of Asacol received two new patents, which will both expire in 2021.\textsuperscript{158} The company then attempted a product hop before the 2013 expiration of the Asacol patents through a marketing and promotion campaign.

However, the new form of Asacol was only approved for moderately active ulcerative colitis.\textsuperscript{159} The older form of Asacol was approved for both the moderate form and the mild form of the disease.\textsuperscript{160} Thus, despite continued efforts to switch all patients to the new form and multiple complaints alleging that this represented unlawful off-label marketing (because the drug was not approved for all patients), the new form did not gain substantial market share.\textsuperscript{161}

The company was not deterred. With Asacol’s patent expiration approaching, the brand-name firm developed and introduced Delzicol, a 400mg tablet that was bioequivalent to Asacol.\textsuperscript{162} In fact, as Internet commentators discovered, Delzicol was merely an Asacol tablet surrounded by a cellulose capsule.\textsuperscript{163} If the capsule was cut open, the original Asacol tablet fell out.\textsuperscript{164} Delzicol did not receive a new grant of exclusivity from the FDA because it was not considered a new molecular entity.\textsuperscript{165} Nevertheless, the capsule allowed the company to obtain a patent—despite the fact that the capsule provides no additional therapeutic benefit.\textsuperscript{166}


\textsuperscript{157} Id. at paras. 38–41.

\textsuperscript{158} Id. at para. 40.

\textsuperscript{159} Id. at para. 39.

\textsuperscript{160} Id.

\textsuperscript{161} Id. at paras. 52–57.

\textsuperscript{162} Id. at paras. 72–75.

\textsuperscript{163} Id. at paras. 85–88.

\textsuperscript{164} Id. at paras. 84–87.

\textsuperscript{165} See Part II above for a discussion of this FDA non-patent exclusivity that provides marketing protection for new drugs with new active ingredients.

\textsuperscript{166} Backing this point up is the fact that Delzicol was approved by the FDA as bioequivalent to Asacol, so it could not have been “medically superior” in any way. End-Payor Plaintiffs’ Class Action Complaint, supra note 156, at para. 81. Given that the active ingredients of Asacol must be released in the gastrointestinal tract to have an effect, Asacol tablets have always been covered with an enteric coating that prevents the pill from breaking down in
The company argued that the change was necessary because a slight modification was also made to an inactive coating ingredient that may have posed safety concerns.167 According to a complaint, however, this ingredient remains part of Asacol tablets sold in other countries, and switching out only this ingredient would not have led to additional exclusivity for Asacol.168 Thus, this switch may have merely been subterfuge to display concern with safety, when the real reasoning was to add the patentable but inoperable cellulose capsule and maintain the company’s supra-competitive profits.

Finally, the company went for the hard switch—it completely removed Asacol from the market, sending all patients to the other form of Asacol or to Delzicol. In a candid conference call, the company’s CEO left no doubts about the strategy: “It’s a hard conversion. We’re stopping—we’re going to stop the shipment of Asacol 400 shortly, and it will be all Delzicol. I think they’re all familiar with what’s going on.”169 The complaint also alleges the involvement of reverse payments and citizen petitions, offering an example of how “multiplicity tactics” are often involved in generic delay.170

Perhaps the most notable recent case in the product-hopping space is the case that may eventually bring about its downfall. Litigation over a product hop involving Namenda, an important Alzheimer’s treatment, reached the Court of Appeals for the Second Circuit in spring 2015.171 In a May decision, a three-judge panel denied drug manufacturer Actavis’ appeal of a preliminary injunction that forced the company to continue selling the old drug alongside its newer product, Namenda XR.172

The old form of Namenda is a twice-a-day treatment for moderate-to-severe Alzheimer’s. In July 2013—notably, three years after its approval by the FDA—Actavis introduced Namenda XR, a higher-dose treatment that could be taken once daily.173 In August 2014, about one year before patents would expire on Namenda IR, Actavis tried to completely pull the old form of the drug from the market. One month later, the New York Attorney General’s office filed a complaint alleging antitrust violations under the Sherman Act and sought a preliminary injunction to force Actavis to continue selling the older formulation. The FTC received the requested injunction in December 2014, and the decision was eventually upheld by the Second Circuit.174

---

167 Id. at paras. 89–103.
168 Id. at para. 83.
170 Id. at paras. 62–64.
172 Id. at 643.
173 Id. at 647–48.
174 Id. at 649–50.
Actavis is important, and not just because it was one of the first cases in which product hopping was found to be potentially anticompetitive. Most important, the Namenda product hop took place in a market that the company completely dominated; Namenda is the only treatment in its class available for Alzheimer’s and the only treatment approved for moderate-to-severe Alzheimer’s.175 Thus, unlike other cases of product hopping where other drugs might be available as an inexact substitute, switching to Namenda XR was the only choice for Alzheimer’s patients who completely depend on the treatment.176

Further, while the company appeared to be offering the benevolent innovation of a once-daily medication, all other Alzheimer’s treatments had already moved to a once-a-day treatment before the introduction of Namenda XR.177 The actions raise questions of whether Actavis had waited to incorporate a known innovation in order to thwart generic entry. Those allegations are heightened by the fact that Actavis failed to introduce the once-a-day form for three years after it was approved by the FDA, timed to less than a year before the patents on original Namenda would expire.178

The development of antagonist strategies such as product hopping has created the opportunity for brand-name firms to dip back into their pool of Generation 2.0 tactics. In particular, product hopping has spawned a new set of “boy scout” clauses, in which the brand-name drug company agrees to refrain from antagonistic behavior.179 One such clause is an agreement not to product hop before generic entry, or to handsomely pay the generic if product hopping occurs. For example, in In re Opana, class action plaintiffs allege that Endo, a brand-name firm, agreed to pay a first-filing prospective generic what amounted to over $102 million, but only if sales of the brand-name drug fell below a certain level in the quarter before the generic launch date.180 In exchange, the generic delayed its entry for over two years.181 However, this significant drop in sales would likely occur only if there was a product hop away from the brand-name drug; thus, the agreement essentially

---

175 See Current Alzheimer’s Treatments, ALZHEIMER'S ASS'N, http://www.alz.org/research/science/alzheimers_disease_treatments.asp [http://perma.cc/E66C-WGLX] (noting that memantine, the drug name for Namenda, is the only NMDA receptor antagonist treatment for Alzheimer’s and was the only treatment approved for moderate-to-severe Alzheimer’s at the time of the product hop). A newly introduced drug approved for moderate-to-severe Alzheimer’s, Namzaric, combines memantine with donepezil, a cholinesterase inhibitor that had already been approved for Alzheimer’s treatment in the United States in 1996. Id. The combination drug, however, is also sold by Actavis.

176 Actavis PLC, 787 F.3d at 654 n.27.


178 Actavis PLC, 787 F.3d at 647–48.

179 See Section IV.C for more discussion of “boy scout” clauses.


181 Id.
functioned as a promise to pay the generic in the event Endo decided to product hop.\textsuperscript{182}

On its face, this agreement appears to actually promote competition by deterring a brand-name from product hopping before the generic could enter. The circumstances of the \textit{Opana} settlement, however, were designed to actually effectuate Endo’s product hop. Complainants allege that the two companies knew before entering into the agreement that the brand-name company would product hop—and in fact, Endo began the FDA approval process for a new version of the brand-name drug just one month after the agreement.\textsuperscript{183}

Therefore, knowing that a product hop was coming, the $102 million payment effectively served as a simple reverse payment to the generic in return for delaying entry until Endo had a chance to complete its product hop.\textsuperscript{184} By the time the generic launched, ninety percent of the product’s market had already switched to the new formulation.\textsuperscript{185} In sum, Endo’s boy scout clause was only one part of a strategy in which a product hop triggered a side deal that essentially served as a reverse payment for delay. Put another way, Endo’s generous invocation of Scout’s honor was in fact an excuse to use a new Generation 3.0 strategy to enter into a Generation 2.0 deal masking a simple Generation 1.0 reverse payment. The weapons may differ—and may be used simultaneously—but the games remain the same.

\textbf{C. REMS-based Delay}

REMS-based delay is another strategy in the Generation 3.0 obstruction toolkit. REMS (Risk Evaluation and Mitigation Strategies) are risk management and safety plans that the FDA can require a pharmaceutical company to implement beyond the standard labeling requirements that apply to most drugs.\textsuperscript{186} Such plans are developed by the pharmaceutical company and then approved and continuously reviewed by the FDA.\textsuperscript{187}

\begin{footnotesize}
\textsuperscript{182} \textit{Id.} at paras. 3, 143–52.
\textsuperscript{183} \textit{Id.} at para. 3.
\textsuperscript{184} \textit{Id.} at para. 149.
\textsuperscript{185} \textit{Id.} at para. 158. The generic also secured a no-AG agreement with regards to Opana ER as well as other side deal considerations, allowing it to recover some of the profits it lost by allowing a product hop. In the absence of the settlement, the generic may have faced competition from an Endo authorized generic when it launched. Instead, it was able to launch as the sole generic product although it faced a market that had shifted to a new version of Opana. The no-AG agreement also helped to make the deal worthwhile for the generic even in the case where Endo failed to product hop and did not trigger the $102 million payment. \textit{Id.} at paras. 156–57.
\textsuperscript{187} \textit{Id.}
\end{footnotesize}
REMS are unique to a particular drug, but they can include the following elements: additional medication inserts to be included with the drug, a campaign or “communication plan” to inform key stakeholders about the risks of the drug, and, most notably, “Elements to Assure Safe Use” (“ETASU”). ETASU are the most restrictive requirement of a REMS program because they directly influence how and when the drug can be used. ETASU can include elements such as patient monitoring or testing while taking the drug, special certification for prescribers or pharmacies, or limitations on how and where the drug can be dispensed (e.g. only in a hospital or certified infusion site). REMS can be modified or completely withdrawn after further assessment.

The number of new requirements that REMS can impose on the sale, distribution, or marketing of a drug have made it ripe for abuse by branded drug manufacturers looking to keep generics out of the market. For example, a common ETASU restricts sales of a particular medication to hospitals and specially certified pharmacies. This creates an obstacle for would-be generic manufacturers looking for generic approval. The generic must prove that it is bioequivalent to the brand-name drug, and testing for bioequivalence requires that the generic applicant use the brand-name drug as a comparison to the generic formulation. Therein lies the problem. A number of cases have involved complaints that the brand-name drug company refused to sell a small amount of their drug to the generic on the grounds that the FDA limits the drug’s distribution to specific outlets, and the generic company is not one of those outlets. As described below, the brand-name company refuses, even as the FDA insists that the company is free to sell to the generic hopeful.

*Actelion* was one of the first cases on this subject when it was filed in 2012. The brand-name company refused to provide samples of two drugs to potential generic companies, which prevented the generic hopefuls from filing their applications. The brand-name company’s position is difficult to fathom. Congress considered the potential for this type of tactic, and the legislation establishing REMS includes a provision specifically stating that an ETASU cannot be used to block or delay approval of a generic. Further,
the FDA has repeatedly said that brands may sell samples to firms for bioequivalence testing without violating their REMS program, even issuing letters to branded manufacturers specifically permitting them to give samples to prospective generics. The legal arguments in the Actelion case focused on whether or not there is a duty to deal on the part of the brand-name company and whether refusal to deal constitutes an antitrust violation. Actelion asserted that it has a right to refuse sale even in the absence of the REMS, while the FTC filed a brief stating that the company’s action may amount to exclusionary conduct. The case ended in a settlement in early 2014.

In a similar case filed against brand-name drug manufacturer Celgene, a generic hopeful alleged that it spent five years trying unsuccessfully to get a sample of Celgene’s Thalomid and another five years trying unsuccessfully to obtain a sample of Celgene’s Revlimid. Although the judge dismissed some claims in the generic’s complaint, she allowed important antitrust claims to survive a motion to dismiss, finding that the generic pleaded with enough detail that Celgene had no “legitimate business reasons” for denying samples.

REMS manipulation, in theory, could be particularly dangerous for generic competition. REMS are not linked to patent protection and can con-

---

196 See Ctr. for Drug Evaluation & Res., U.S. Food & Drug Admin., Risk Evaluation and Mitigation Strategy (REMS) Public Meeting 270–72 (July 28, 2010) (statement by Jane Axelrad, Associate Director of Policy, Ctr. for Drug Evaluation and Res.), http://www.fda.gov/downloads/Drugs/NewsEvents/UCM224950.pdf [https://perma.cc/V22K-99B7] (asserting that REMS should not be a barrier to acquiring generic samples). In part, these letters came about after a citizen petition filed in 2009 by Dr. Reddy’s asking the FDA to issue guidance regarding the use of REMS to block or delay generic entry. It also asked the FDA to establish a procedure by which the FDA would provide letters on behalf of generic applicants to explain that the generic will meet the REMS safe use requirements that might be implicated in bioequivalence testing. See Citizen Petition from Kumar Sekar, Senior Dir., to Div. of Dockets Mgmt., U.S. Food & Drug Admin., No. FDA-2009-P-0266-0001, at 10 (June 10, 2009), http://www.fdalawyersblog.com/Dr_Reddys_Laboratories_Inc_-Citizen_Petition.pdf [https://perma.cc/95H9-5KXL]. Dr. Reddy’s was attempting to obtain samples of Celgene’s Revlimid and Thalomid, which are also the subject of another ongoing REMS-based lawsuit.


198 Greene, supra note 193; Lance Duroni, Actelion Denied Judgment in Tracleer Antitrust Suit, Law360 (Oct. 21, 2013, 8:00 PM), http://www.law360.com/articles/481879 [http://perma.cc/SU7D-S4WV]. Although a settlement may represent a party’s rational calculation of the strength of its case and the costs of continuing to litigate, it may also represent the strategic choice to abandon a case or pay off the other side if damaging information might emerge or dangerous precedents might be set.


200 Id. at *17–18; see also Carrier, Levidow & Kesselheim, supra note 198, at *13–14 (discussing this case).
continue indefinitely, even after the expiration of all exclusivities. Thus, if a company, hiding behind a restrictive REMS, refuses to allow samples to generic hopefuls, the brand-name company could continue its monopoly past the end of the patent term. Even if the company is eventually forced to share samples, as described above, every month of delay is valuable.

Furthermore, a restricted distribution scheme does not even need a REMS (or an active patent) to be effective in blocking generic competition. For example, in September 2015, Turing Pharmaceuticals and its founder, Martin Shkreli, became the subject of intense scrutiny after raising the price of a drug by almost 5,500%. Turing had bought the rights to Daraprim (pyrimethamine), an antimalarial drug also used for treatment of infections common in HIV-positive patients, for $55 million. The company then immediately raised the price of the drug from $13.50 a tablet to $750 a tablet. A thirty-day course of the drug became $20,000, rather than just $400 before the increase.

The mere magnitude of the price increase for a potentially life-saving drug—and one that had already been off-patent for decades—led to immediate public outrage, causing Shkreli to eventually promise a price reduction. Behind the price increase, however, was also a REMS-like tactic meant to block potential generic competition. When Turing acquired the rights to Daraprim, it maintained a restricted distribution system originally put in

---


204 Id.

Drug Wars

place by Impax, the previous owner. As discussed earlier in this section, restricted or controlled distribution is often a requirement of a REMS when a drug presents special concerns regarding safety, administration, or storage. Yet Impax (and later, Turing) seems to have instituted a restricted distribution system for no safety reason whatsoever, making the drug only available through Walgreen’s Specialty Pharmacy. Along with creating access problems for hospitals, the move in part seemed to be designed to make it difficult for generics to gain access to samples.

Comments from Turing executives support this implication. In response to the Daraprim pricing controversy and the potential for generic competition, Jon Haas, director of patient access at Turing, said the following: “Most likely I would block that purchase [by a generic]. We spent a lot of money for this drug. We would like to do our best to avoid generic competition. It’s inevitable. They seem to figure out a way [to make generics], no matter what. But I’m certainly not going to make it easier for them.” The comments suggest a concerted effort to block generic competition, and a failure to accept the intent of the Hatch-Waxman’s system for introduction of generic drugs. In addition, although Turing executives may have spoken more directly than others, actions in many corners of the pharmaceutical industry reflect a similar mindset. Turing’s actions, specifically the use of restricted distribution to block competition, are now under investigation by the New York attorney general. U.S. lawmakers have also called on the FTC to look into the Turing business model.


207 Id.


209 Carrier, Levidow & Kesselheim, supra note 198.


As Carrier, Levidow, and Kesselheim have detailed, the Daraprim system was not the first time a Skhreli-led company implemented a restricted distribution system.\textsuperscript{213} Notably, Skhreli’s previous company, Retrophin, bought the rights to a rare kidney-disorder drug called Thiola. Retrophin increased the price of the drug 2000% from $1.50 to $30 a pill, but it also created a still-active closed distribution system known as “Thiola Total Care.”\textsuperscript{214} This system requires a patient and the patient’s doctor to fax enrollment forms to Retrophin, which then manages direct shipments not through an online system but only over the phone.\textsuperscript{215} Documents that Turing turned over to Congress in advance of a February 2016 hearing revealed that, internally, it was known that “[e]xclusivity (closed distribution) creates a barrier and pricing power.”\textsuperscript{216}

Restricted distribution schemes, whether they involve a REMS or not, also may be deployed to prevent generic substitution by pharmacists. In another story that captured the public’s attention, federal prosecutors announced an investigation of Valeant Pharmaceuticals, also pilloried for acquiring medicines and then substantially increasing prices.\textsuperscript{217} That accusation, however, was only the first of a series of allegations that would unfold against Valeant. Just days later, journalists discovered that Valeant had a deep relationship with a specialty pharmacy known as Philidor that essentially only filled prescriptions for Valeant’s drugs and dermatology creams.\textsuperscript{218} This investigation in turn led to the discovery of numerous pharmacies and subsidiaries covertly linked to Valeant.\textsuperscript{219}

The link between Valeant and specific specialty pharmacies allowed Valeant to ensure that its drugs were filled instead of generic prescriptions. Doctors would submit prescriptions for Valeant drugs to a mail-order spe-

\textsuperscript{213} See Carrier, Levidow & Kesselheim, supra note 198, at *20–21.

\textsuperscript{214} Id.

\textsuperscript{215} Thiola Total Care Hub, THIOLA, http://www.thiola.com/hub [http://perma.cc/2JQ6- TAA2]. Notably, although it may be a technical error, the enrollment form on the Total Care Hub website automatically fills in the bubble for “dispense as written.” Patient Enrollment Form for Thiola Total Care Hub, THIOLA, http://www.thiola.com/assets/pdf/THI010V2.pdf [https://perma.cc/C6LY-64Q3].

\textsuperscript{216} See Carrier, Levidow & Kesselheim, supra note 198, at *21 (citing Memorandum from Democratic Staff to Democratic Members of the Full H. Comm. on Oversight and Gov’t Reform Regarding Documents Obtained by Comm. from Turing Pharm. 3 (Feb. 2, 2016), http://democrats.oversight.house.gov/sites/democrats.oversight.house.gov/files/documents/ Memo%20on%20Turing%20Documents.pdf [https://perma.cc/C2KH-XSXY]).


cialty pharmacy, the prescription would be sent to the patient, and then the pharmacy would work with insurance companies to secure reimbursement. When the prescription is sent to a specialty pharmacy that only deals with specific drug brands, however, it is very unlikely that any substitution will take place to dispense a generic or over-the-counter medicine instead of the brand-name drug. As another company using a similar business model disclosed in a regulatory filing, the mail-order prescriptions “are less likely to be subject to the efforts of traditional pharmacies to switch a physician’s intended prescription of our products to a generic or over-the-counter brand.” That company, Horizon, reportedly charged $1,500 a month for a medication called Duexis that simply combined ibuprofen and the active ingredient in Pepcid.

The brunt of the costs of this scheme falls on insurers and not patients, perhaps intentionally so that patients and doctors do not feel the sticker shock of high prices. Nevertheless, games like these certainly would not help lower insurance premiums, nor would they help rationalize national spending on health care. Moreover, when insurers balked at the high cost of Valeant prescriptions, Philidor and other pharmacies allegedly took drastic action to secure reimbursement, including modifying prescription codes to make it appear as if the doctor specifically requested that a prescription be “dispensed as written” with Valeant-branded medication. As a result, these schemes continually blocked generic competitors from participating in the market for the medication.

Aside from restricted distribution programs, other REMS-based schemes have appeared as well. Frequently, a REMS program will ask a drug’s manufacturers to develop a more detailed medication guide or a communication plan to inform doctors and patients about the elevated risks of a drug. For example, Gilenya (fingolimod), an immunosuppressant that treats relapses of multiple sclerosis, has a REMS that requires a communication plan with materials for doctors and patients, as well as an FDA-mandated pregnancy registry.

When there are multiple manufacturers of a drug—for example, a brand and generic—the FDA often requires all parties to develop and agree on the same REMS program, known simply as a Single Shared REMS program.

---

221 Id.
222 Id.
Harvard Journal on Legislation

[Vol. 53

(“SSRS”). In particular, generic entry can be conditioned on FDA approval of a SSRS. The idea that a brand-name company will be willing to cooperate in streamlining the approval of a generic seems optimistic at best. When brand name drug makers are able to delay entry by a refusal to cooperate, it is not a surprise that they have taken advantage of it, creating another form of generic delay. The generic cannot get its drug approved until the brand-name company cooperates, and the brand-name company avoids cooperating to keep the generic off the market. It could be compared to a high school group project where one member not only refuses to complete a fair share of the work but also has an incentive to see the project fail in order to sabotage the grades of fellow group members.

The most notable case dealing with this strategy is In re Suboxone. Suboxone is used for the treatment of addiction to opioids, such as heroin and oxycodone. The drug has saved the lives of many addicts, but with serious consequences. Suboxone has become a street drug of its own, and it comes with the risk of severe side effects and withdrawal symptoms. Suboxone includes both a semi-synthetic opioid and a drug used to combat the effects of an opioid overdose (with unpleasant side effects), which is included for the sole purpose of deterring potential users from injecting the drug intravenously.

Suboxone is perhaps the poster child for a drug needing a comprehensive REMS program. Its REMS program includes a medication guide, a checklist that physicians must follow when prescribing the drug, federal authorizations for prescribers, limits on how much medication can be initially prescribed, an intensive monitoring program requiring frequent patient return visits, and monitoring on the part of manufacturers, which can even include “surveillance” and “street ethnography” to detail patterns of abuse.


227 Id.


229 See Sontag, supra note 229.

Suboxone is also a blockbuster with over $1.55 billion in sales in 2012, linked to an explosion of painkiller and heroin abuse in the United States. Thus, with the brand-name company, Reckitt Benckiser, nearing the end of its exclusivity for Suboxone tablets in 2009 and generic entry looming on the horizon, the company undertook an extraordinary set of actions to maintain a monopoly on the Suboxone franchise. Complainants allege tactics including an anti-competitive product hop, sham citizen petitions, and REMS abuse.

Specifically, as exclusivity was about to expire on Suboxone tablets, complaints allege that Reckitt began to develop a film version of Suboxone with the intention of product hopping from tablet to film form. The timing was off for the company, however, because the final exclusivities for the tablet were scheduled to expire about eleven months before the FDA approved the film version. The resulting eleven-month gap could have been a prime opportunity for a generic to enter and gain market share before the FDA approved the Suboxone film. To effectuate a product hop, complainants argue that the brand-name company undertook a massive sales and marketing campaign to “promote” the idea that the tablet version of Suboxone presented safety concerns, which would be alleviated by the Suboxone film version. The campaign claimed that there was a high risk of pediatric overdose from a bottle of Suboxone tablets, a risk remedied by the packaging for the film version because the films are packaged individually. Notably, unit-dose packaged tablets are available in all other markets where Suboxone is sold, other than in the United States. In other words, the problem

---

232 Sontag, supra note 229.
234 Id. at para. 15.
236 Id. at para. 15.
237 Id.
239 End Payor Plaintiffs’ Consolidated Amended Class Action Complaint, supra note 234, at paras. 21, 28. Further, it was argued that the film may exacerbate safety concerns regarding pediatric exposure. Since the film dissolves more quickly than the tablet, it may be difficult to prevent a child from being exposed to the medication once they put it in their mouth. Also, the potential for abuse may increase since the film’s dissolvability can make its use more discrete.

---

R
232 Sontag, supra note 229.
234 Id. at para. 15.
236 Id. at para. 15.
237 Id.
239 End Payor Plaintiffs’ Consolidated Amended Class Action Complaint, supra note 234, at paras. 21, 28. Further, it was argued that the film may exacerbate safety concerns regarding pediatric exposure. Since the film dissolves more quickly than the tablet, it may be difficult to prevent a child from being exposed to the medication once they put it in their mouth. Also, the potential for abuse may increase since the film’s dissolvability can make its use more discrete. In re Suboxone, 64 F. Supp. 3d at 674; see also Sontag, supra note 229 ("‘It’s such a thin strip they’ll put it in the Holy Bible, let it melt and eat a page right out of the good book,’ said Ken Mobley, a jailer in Whitley County, Ky.").
could have been remedied with the tablets, but the company had not seen fit to provide that resolution in the U.S. market.

Despite the campaign, the possibility of generic tablet entry continued to be a problem for Reckitt. Thus, the company sent multiple letters and applications to the FDA proposing a REMS because of the risks of abuse and pediatric exposure. This request was approved, and the FDA required that the generic and branded Suboxone share the same REMS. Unsurprisingly, attempts at cooperation between Reckitt and the prospective generics proved unsuccessful. Eventually, the generics gave up, applying for and receiving a waiver to create a REMS without the branded drug company—the first time such a waiver had ever been granted.

The nine-month period during which generics and the brand name company could not come to an agreement on a REMS may have been worth upward of $1 billion in Suboxone sales. This is an enormous sum to result from a disagreement presumably not over the medication itself, but on how its use would be monitored and how the risks would be explained to the public.

In the resulting lawsuit, the judge in 2014 dismissed the generic company’s standalone claim that Reckitt’s actions regarding the REMS amounted to an antitrust violation. The saga of Suboxone continues in the next sec-

---

243 Assuming $1.55 billion in sales of Suboxone in 2012. This assumes that the REMS delay was the only issue standing in the way of generic approval, which is not a fully unreasonable assumption. As will be discussed below, in Section D, immediately before the generics applied for a REMS waiver, Reckitt announced a withdrawal of Suboxone tablets from the market and filed a citizen petition asking for the generic ANDA to not be approved. Immediately after the citizen petition was dismissed in early 2013, the ANDAs were approved. Thus, it is possible that generic entry could have been approved immediately after the REMS waiver was approved had Reckitt not taken further action.
244 In re Suboxone, 64 F. Supp. 3d at 688.
tion, however, with further complaints of anticompetitive behavior. In short, it is clear that although the FDA would like to get “[all the parties] to play nicely together” on the playground, mere talk is unlikely to achieve this goal when billions are on the line. As the FDA admitted in another REMS case, the agency simply lacks an effective mechanism to force the two parties to reach agreement.

D. Delay via Citizen Petition

Citizen petitions offer another way to create obstacles to generic entry. Since 1979, the FDA has allowed the public to request that the agency “issue, amend, or revoke a regulation or order or take or refrain from taking any other form of administrative action.” Although the program applies to all products under the FDA’s jurisdiction, the majority of citizen petitions are related to pharmaceuticals, rather than food, cosmetics, or medical devices.

Many pharmaceutical petitions are relatively benign. A number ask the FDA to allow a generic to certify to a brand name or reference drug no longer on the market or to allow approval of a generic that differs slightly from the brand-name drug in regards to characteristics such as strength or dosage form.

Other petitions, however, are troubling, particularly some of the petitions that assert concerns regarding a generic application or request that the

---

245 See infra Section V.D.
246 CTR. FOR DRUG EVALUATION & RES., supra note 196, at 272 (statement by Jane Axelrad, Associate Director of Policy, Center for Drug Evaluation and Research) (discussing difficulties of getting parties to work together to set up a joint REMS). At least one bill has been introduced in Congress tackling the two main forms of REMS abuse—denial of samples for generic testing, and unwillingness to cooperate on single-shared REMS. The bill would require brand-name drug companies to provide samples (after FDA approval) to prospective generics at a nondiscriminatory, commercially reasonable, market-based price. It would also streamline the process by which ANDA applicants can receive a waiver from the single-shared REMS process if they are able to demonstrate that negotiations were not successful after 120 days. See Fair Access for Safe and Timely Generics Act of 2015, H.R. 2841, 114th Cong. (2015).
251 See id.
generic applicant conduct new, time-consuming studies before approval.\textsuperscript{252} As described previously, even if a petition costs hundreds of thousands of dollars to file, the investment could pay off. The value of the delay could be lucrative, even when the petition is quickly rejected.

\textit{Suboxone}, the case that featured creative product hopping and allegations of REMS abuse, again provides a troubling tale. As described in the previous section, the generics were forced to get a REMS waiver because they were unable to get the brand-name company, Reckitt, to cooperate. Immediately prior to the generic REMS waiver request, which would have allowed the generic to move forward if and when approved, Reckitt announced that it was completely pulling Suboxone tablets from the market (but did not immediately do so).\textsuperscript{253} The company cited safety concerns related to pediatric exposure, and it followed up on the same day with a citizen petition asking the FDA to refrain from approving any generic application for Suboxone.\textsuperscript{254} In its citizen petition, the brand-name company again cited pediatric exposure issues to demand that medications—such as generic Suboxone—come with “targeted educational interventions on the risk of pediatric exposure” and unit-dose packaging.\textsuperscript{255}

The FDA has a process that allows an application to move forward for a generic version of a drug no longer on the market, if the FDA determines that the drug was not removed for safety reasons.\textsuperscript{256} The safety move coupled with the citizen petition may have been intended to block the generic from utilizing this pathway.

Complainants in \textit{In re Suboxone} allege that this citizen petition was a sham merely meant to block generic approval.\textsuperscript{257} Specifically, the requested labeling measures for generic Suboxone were never required for the brand-name Suboxone tablets. In addition, the FDA does not have the ability to require that a generic filer add labeling not approved for the brand-name drug.\textsuperscript{258} Most important, Reckitt continued to sell Suboxone tablets in bulk and without unit-dose packaging even after it made the petition requesting these restrictions for the generic version.\textsuperscript{259}

\textsuperscript{252}Carrier & Wander, supra note 141, at 261.
\textsuperscript{253}Id.; see Citizen Petition from Reckitt Benckiser Pharm., Inc. to Div. of Dockets Mgmt., U.S. Food and Drug Admin. (Sept. 5, 2012) [hereinafter Citizen Petition from Reckitt Benckiser], https://www.naabt.org/documents/Reckitt_Benckiser_Pharmaceuticals_Inc_2012_FDA_Citizen_Petition.pdf [https://perma.cc/G4Z3-BFTA].
\textsuperscript{254}Id.
\textsuperscript{255}21 C.F.R. § 314.161 (2015). A generic can file a citizen petition asking for an official determination of whether the reference drug was “withdrawn for safety or effectiveness reasons.” If it is determined that the drug was not withdrawn for those reasons, the drug will be relisted for the purposes of ANDA submissions.
\textsuperscript{256}In re Suboxone, 64 F. Supp. 3d at 676.
\textsuperscript{257}Id.
\textsuperscript{258}Id. at 676–77.
The FDA denied the brand-name company’s citizen petition and immediately thereafter granted approval for two generic versions of Suboxone tablets. In its denial of the petition, the FDA noted that the brand-name company’s “own actions . . . undermine, to some extent, its claims with respect to the severity of this safety issue.” Further, the FDA noted that the brand-name company’s decision to pull Suboxone from the market so close to generic competition “cannot be ignored,” explaining in a footnote that Reckitt got access to private information about the potential timing for generic applications because the generics volunteered this information in an attempt to get the company to cooperate in REMS creation. The FDA explicitly said it was not denying the petition for failing to raise a valid scientific or regulatory issue or for purposeful obstruction of a generic application, preferring to focus on the lack of merits of the petition’s safety concerns. The Agency, nevertheless, made its opprobrium clear by referring the company’s conduct to the Federal Trade Commission for review.

Still, despite the FDA’s complete rebuttal of all of the brand-name company’s claims, the citizen petition resulted in five months of delay. Given sales of approximately $1.5 billion in 2012, the five months of delay was worth over $600 million in unchallenged sales to the brand-name company. That is a remarkably strong incentive for companies to engage in this type of tactic.

As always, the consumer pays the cost in the form of higher prices.

The FDA and the Federal Trade Commission have long recognized that the citizen petition process could be subject to abuse, expressing concerns and proposing modifications as early as 1999.

260 Id. at 676.
262 FDA Response to Reckitt Benckiser, supra note 261, at 15 & n.53.
264 Suboxone Sales Data, DRUGS.COM (Feb. 2014), http://www.drugs.com/stats/suboxone [https://perma.cc/23F5-W3D6]. As with all calculations of the value of delay in this Article, the assumption is made for ease that, without the delay, generic competition would immediately drop Reckitt’s revenues on Suboxone to zero.
265 See Darren S. Tucker, FDA Citizen Petition: A New Means of Delaying Generic Entry?, 20 ANTITRUST HEALTH CARE CHRON. 10, 11 (2006); Citizen Petitions: Actions That Can be Requested by Petition; Denials, Withdrawals, and Referrals for Other Administrative Ac-
such abuse by enacting a new rule in 2007 that when a citizen petition could delay generic approval, the FDA must take final action on the petition within 150 days, unless the delay is necessary to protect the public health. To further discourage baseless or strategically-timed petitions, filers of citizen petitions must provide the date when they first became aware of the issues raised. Finally, the FDA also was granted the power to deny a petition at any time if it believes a petition was “submitted with the primary purpose of delaying the approval of an application and the petition does not on its face raise valid scientific or regulatory issues.”

In the case of Suboxone, however, the regulatory process worked entirely as intended, and the brand-name company’s petition was denied exactly 150 days after the date it was filed. Nevertheless, the petition resulted in five months of delay and an estimated $600 million of higher priced sales for the company. Thus, even when the bell rings on time as Congress intended, brand-name companies still can use the process to engage in costly delays. The various amendments also do not seem to have discouraged the filing of non-meritorious citizen petitions requesting the delay of a generic. Between fiscal years 2008 and 2013—the period in which the amendments have been in place—124 delay petitions were filed and only eight were fully


269 See Suboxone Sales Data, supra note 264 (listing Suboxone sales as $1.5 billion in 2012, or $600 million over five months).
granted. Moreover, the number of citizens petitions requesting delay has not declined since passage of the amendments.

The amendment’s most biting provision also has proven difficult to apply. Recall that the statute allows the FDA to summarily deny petitions, but only when they are both submitted for the main purpose of delay and raise no valid scientific or regulatory issues on their face. Proving both of these requirements concurrently has turned out to be quite difficult. In fact, since the amendments took effect in fiscal year 2008, the FDA has never applied the summary denial provision.

In theory, the wounded would-be generic could file a lawsuit asserting that the brand-name company engaged in anticompetitive behavior by submitting a sham citizen’s petition. Such a lawsuit is unlikely to succeed, however. The difficulty flows back to Noerr-Pennington, a line of Supreme Court cases from the 1960s that establishes a general right to petition the government without fear of antitrust liability. Noerr-Pennington does carve out an exception that allows antitrust liability when petitioning the government is a sham meant merely to interfere with a competitor. The Court, however, has set an extremely high standard for demonstrating that a legal petition is a sham. Specifically, the petition must be objectively baseless, which requires a showing that no reasonable petitioner can realistically expect success on the merits, as well as subjectively baseless, which requires a showing that the petition tries to conceal an attempt to interfere directly

---

270 U.S. F OOD & D RUG A DMIN., S IXTH A NNUAL R EPORT TO C ONGRESS ON D ELA YS IN A PPROVALS OF A PPLICATIONS R ELATED TO C ITIZEN P ETITIONS AND P ETITIONS FOR S TAY OF A GENCY A CTION F OR FISCAL Y EAR 2013, at 6–7 (2013) [hereinafter FDA SIXTH A NNUAL R EPORT FOR FY 2013], http://www.fda.gov/downloads/AboutFDA/CentersOffices/Office-ofMedicalProductsandTobacco/CDER/ReportsBudgets/UCM423291.pdf [https://perma.cc/L4EF-2CP3]. Thirty-one of these petitions were denied in part or granted in part. Id. at 6. However, as Carrier notes, these “mixed decisions” are often a formality and not truly a partial finding in favor of the petitioner. The requests “granted in part” are often trivial requests for bioequivalence studies that have either already been completed, are in progress, or would certainly be required by the FDA even in the absence of the citizen petition. Carrier & Wander, supra note 141, at 266–68.

271 FDA SIXTH A NNUAL R EPORT FOR FY 2013, supra note 270, at 5; see generally Carrier & Wander, supra note 141.


with competition through the administrative process.276 This burden on plaintiffs is crushing.

Still other pathways exist for abusing the citizen petition process, despite the limitations imposed by the amendments. As the FDA itself has noted, the 150-day clock applies only when a citizen petition has the power to delay generic approval.277 If a citizen petition is filed before any generic application is submitted or before any generic application is ready for approval under the Hatch-Waxman rules, the 150-day deadline does not apply.278 Thus, citizen petitions filed before a generic application is ready can serve as yet another obstacle, perhaps combined with strategies already in play.

Finally, the 150-day limit applies to consideration of each petition, rather than providing a 150-day maximum for how long generic approval can be put on hold. That leaves the door open for what the FDA has called “serial” petitions, in which multiple petitions are filed about the same drug, frequently from the same petitioner.279 By filing separate petitions at staggered times on disparate issues, a brand-name company can force the FDA to spend time responding to each petition, thereby potentially lengthening the total delay-by-citizen-petition far beyond 150 days.280 Thus, as with REMS delay, codified congressional condemnations of a practice281 are just a new rule for which manufacturers must find a work-around. They are about as effective as admonishing school children to speak politely to each other on the playground.

---

276 Professional Real Estate Inv’rs. v. Columbia Pictures Indus., 508 U.S. 49, 60–61 (1993); see also Silber, Lutinski & Taylon, supra note 272, at 30–31; Feldman, supra note 13, at 166–67.

277 FDA SIXTH ANNUAL REPORT FOR FY 2013, supra note 270, at 6.


279 FDA SIXTH ANNUAL REPORT FOR FY 2013, supra note 270, at 7.

280 Id.; WILSON SONSINI GOODRICH & ROSATI, supra note 278, at 2. In the FDA’s Fourth Annual Report on delays related to citizen petitions for the 2011 fiscal year, it noted the following about serial petitioning: “[F]or example, the agency received its fourth 505(q) petition relating to the approval of ANDAs for topical ophthalmic products and a third 505(q) petition related to Doryx (doxycycline). The various submissions raised different scientific issues, requiring serial review of different arguments, rather than one comprehensive review of all pertinent arguments.” U.S. FOOD & DRUG ADMIN., FOURTH ANNUAL REPORT TO CONGRESS ON DELAYS IN APPROVALS OF APPLICATIONS RELATED TO CITIZEN PETITIONS AND PETITIONS FOR STAY OF AGENCY ACTION FOR FISCAL YEAR 2011, at 6 (2011), http://www.fda.gov/downloads/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobaccos/CDER/ReportsBudgets/UCM 369782.pdf [https://perma.cc/MZ7V-DEZG].

281 Referring to the REMS statute passed by Congress clarifying that a REMS cannot be used to block an ANDA and Section 505(q) for citizen petitions.
E. Preventing the “Skinny Label”: Blocking Section viii Carve-Outs

As Generation 3.0 games advance, an additional tactic relates to what is known as “the skinny label.” Many patents on pharmaceuticals do not cover substances and chemical formulas, but particular uses of a drug. Hatch-Waxman, however, allows a generic applicant to seek approval for a version that will cover only uses of the drug not protected by patents or FDA exclusivities.282 Applicants also can ask permission to omit some of the brand-name drug’s labeling language from the generic label if that language relates to uses that are protected.283 These are known as section viii carve-outs or “skinny labels.” For example, the brand-name company’s patent could be a “method-of-use” patent, which protects only certain indications of the drug, with “indication” referring to a reason why the drug is administered (e.g. “for treatment of Helicobacter infections”).284 This could occur when the drug’s chemical formula had been patented or used in the past, and the company could receive only a more limited patent for a new indication of the medicine. Under these circumstances, the generic could request approval for uses of the medication other than those protected by the use patent.

Request for a “skinny label” could also apply when the brand-name drug company has received special FDA exclusivities available for circumstances such as use of a drug for orphan categories or new pediatric indications. A generic could file a request indicating that it does not seek approval for the protected uses. Similarly, if a brand-name drug is only protected by non-indicatory patents or FDA exclusivities for reasons such as how the drug should be administered or its bioavailability under certain conditions, a generic applicant could state that their drug would not be subject to the protected labeling.285

Generally, these carve-out requests are approved unless they cause the generic to be less safe or effective than the brand-name drug for all remaining, non-protected uses.286 Such carve-outs or “skinny labels” can be an effective way for generics to bypass weak or limited patents that brand-name companies may add near the end of a drug’s patent term in the hopes of holding onto its exclusive market position for all uses of a drug.

284 The example indication of “use for treatment of Helicobacter infections” comes from the FDA’s listed use code for a method-of-use patent listed for Nexium, the popular acid reflux medication—although this use refers to using Nexium to treat bacterial infections often associated with stomach ulcers and cancer. See Patent and Exclusivity Search Results from Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations, U.S. Food & Drug Admin., http://www.accessdata.fda.gov/scripts/cder/ob/docs/patexclnew.cfm?Appl_No=021153&Product_No=002&table1=OB_Rx [https://perma.cc/TJ9B-HUWL] (last updated Feb. 2016) (patent no. 8,466,175 at the bottom of the list); U.S. Patent No. 8,466,175 (filed Nov. 17, 2011). The patent was filed more than ten years after Nexium first received FDA approval.
286 Id.
For every action, however, there is an equal and opposite reaction, and that is certainly the case for carve-outs. Under Hatch-Waxman, when a generic application requests only section viii carve-outs (but contains no Paragraph IV certifications), that application does not trigger the artificial act of patent infringement that allows for litigation and a 30-month stay on approval. Thus, the generic application should be eligible for immediate approval.287 Undaunted, brand-name companies file citizen petitions, arguing that the carve out should be disallowed. These petitions generally argue that the requested carve-out contains information related to the safety or efficacy of the drug, and that such information cannot be removed from the label.288

A generic could, indeed, be attempting disingenuously to get around the Hatch-Waxman litigation process by removing certain uses from the label knowing that physicians may prescribe the drug for all uses, nonetheless.289 The off-label use of medication is a widespread phenomenon that affects many aspects of pharmaceutical law.290 Nevertheless, there are clear instances of brand-name companies making small labeling changes or securing


289 Brand-name drug companies have expressed concern that carve-outs only remove uses and indications in name only—once on the market, the generics could be prescribed and used “off-label” for all uses approved for the brand-name version. See Citizen Petition from Robert Church & David Fox, Hogan Lovells US LLP on behalf of Spectrum Pharmaceuticals, Inc., to Div. of Dockets Mgmt., U.S. Food & Drug Admin., No. FDA-2014-P-1649, at 12 (Sept. 30, 2014), http://www.regulations.gov/#/documentDetail D=FDA-2014-P-1649-0001 [https://perma.cc/8KW0-YQ5N]. However, the FDA has refused to accept this as a rationale for not approving a carve-out, even in cases where the reference listed drug holder says off-label use could implicate safe and effective use of the drug. See Letter from Janet Woodcock, Dir., Ctr. for Drug Evaluation & Research, to Robert Church & David Fox, Hogan Lovells US LLP, No. FDA-2014-P-1649, at 13–14 (Feb. 24, 2015), http://www.regulations.gov/#/documentDetail D =FDA-2014-P-1649-0005 [https://perma.cc/L5Q9-A6MY]. The FDA said requiring this type of “foreseeable use” analysis is “inconsistent with our long-standing policy of not interfering with the practice of medicine,” and noted that a circuit court already rejected this argument as a bar to generic approval. See id. at 14 n.27 (citing Sigma-Tau Pharm., Inc. v. Schwetz, 288 F.3d 141 (4th Cir. 2002)).

290 For example, pharmaceutical companies have enjoyed considerable success in recent years in convincing courts that FDA restrictions on truthful statements about off-label uses of drugs may violate free speech. See generally United States v. Caronia, 703 F.3d. 149 (2d Cir. 2012); Amarin Pharm., Inc. v. U.S. Food & Drug Admin., 119 F. Supp. 3d 196 (S.D.N.Y. 2015). For a discussion of the widespread off-label uses of drugs, see Amarin, 119 F. Supp. 3d at 200–01.
weak method-of-use patents and then filing citizen petitions to block the carve-out requests that follow.291

The history of Skelaxin, while complicated, is one of the most demonstrative in this area, showing how adding one or two method-of-use patents along with clever labeling can lead to years of delay. Skelaxin, the brand-name for the well-known muscle relaxant metaxalone, was first approved back in 1962.292 The drug did not face the threat of generic competition for over thirty years, even though the initial patent on the active ingredient expired in 1979.293 The competitive landscape changed, however, in 2001, when a company filed for approval to market generic Skelaxin.294

With generic competition on the horizon, the brand-name drug company went to work on extending the monopoly market for the drug. In 2001, the company conducted a study measuring the bioavailability when Skelaxin is taken on a full stomach compared to its bioavailability in a fasting state.295 The study showed that the bioavailability of Skelaxin increases when taken with food—in particular, a “high fat meal.”296 Next, the brand-name company filed for and received two patents in 2002 on the method of “increasing the bioavailability of metaxalone” by taking it with food.297 In June 2002, the FDA approved a labeling amendment for Skelaxin, adding a

291 Brand-name companies also have sought to block carve-outs by modifying the “use codes” associated with a given patent in the Orange Book. Use codes provide a brief description of what use of the drug is covered by the listed patent, and brand-name companies have been accused of trying to broaden the scope of use codes to prevent a section viii carve-out. Like the patents listed in the Orange Book, use code information is not verified by the FDA. In Caraco v. Novo Nordisk, 132 S. Ct. 1670 (2012), however, the Supreme Court found that generic manufacturers can file a statutory counterclaim seeking correction of an inaccurate use code.


294 Ctr. for Drug Evaluation & Research, U.S. Food & Drug Admin., Application No. ANDA 40-445, Approval Package for Abbreviated New Drug Application Approval 211 (Mar. 31, 2010) [hereinafter ANDA 40-455 Approval Package], http://www.accessdata.fda.gov/drugsatfda_docs/nda/2010/040445Orig1s000.pdf [https://perma.cc/QPJ4-CE7E] (indicating, in the “Factual Background” of a 2010 Memorandum from Martin Shimer to the Dep’t of Heath & Human Servs., that ANDA 040445 was submitted on September 5, 2001). Although all relevant patents had expired at the time of filing, the generic did not receive immediate approval because of chemistry and bioequivalence problems that caused at least two years of delay before the relevant saga begins. Id.


296 Id.

“pharmacokinetics” section to the drug’s labeling with information about the food effect study.\footnote{298}{Letter from Lawrence Goldkind, Deputy Dir., Div. of Anti-Inflammatory, Analgesic, & Ophthalmic Drug Prods., U.S. Food & Drug Admin., to Linda B. Fischer, Dir. Regulatory Affairs, Elan Pharm., Inc. (June 20, 2002), http://www.accessdata.fda.gov/drugsatfda_docs/appletter/2002/13217s044ltr_2.pdf [https://perma.cc/5LRG-A2JX] (approving new labeling); see also U.S. FOOD & DRUG ADMIN., APPROVED LABEL FOR SKELAXIN (2002), http://www.accessdata.fda.gov/drugsatfda_docs/label/2002/13217s036lbl.pdf [https://perma.cc/PDU9-6YX6].} With two new patents acquired with expiration dates in 2021, the brand-name company seemed primed to hold on to the Skelaxin market for at least a few additional years.\footnote{299}{In 2004, the brand-name drug company complicated matters by withdrawing the 400mg form of Skelaxin and replacing it with a newly-approved 800mg version. While another way in which generic competition was frustrated, it is outside of the scope of this current discussion (and, as discussed below, eventually became moot in the generic approval discussion).}

Now facing two method-of-use patents blocking generic approval, the generic company filed a citizen petition with the FDA in January 2003 asking the agency to restore the previous labeling without the bioavailability data or at least make a declaration that the old label was not withdrawn for safety or effectiveness concerns.\footnote{300}{ANDA 40-455 APPROVAL PACKAGE, supra note 294, at 213 (indicating in row 3 of the table in “Factual Background” of a 2010 Memorandum from Martin Shimer to the Dep’t of Heath & Human Servs. that there was a citizen petition in January 2003 requesting that the original label of Skelaxin be restored).} In essence, the generic was asking whether this labeling information would be eligible for a labeling carve-out. While not approving the generic company’s citizen petition, the FDA filed a “Dear Applicant” letter in 2004, confirming that the bioavailability information could be carved out of generic labeling.\footnote{301}{Dear Applicant Letter from Gary J. Buehler, supra note 295, at 1.}

This was a novel case for the FDA, because Skelaxin has only one indication—“relief of discomforts associated with . . . musculoskeletal conditions.”\footnote{302}{Id. at 1.} Thus, the generic company was not asking to simply carve out a patent-protected use; it was instead seeking to remove labeling information.\footnote{303}{Id. at 3.} The FDA ruled, nevertheless, that removing the data would not render generic Skelaxin less safe or effective than the brand-name drug.\footnote{304}{Id. at 1–5.} In rendering its decision, the FDA relied on the fact that the study did not result in any changes to the dosing instructions or the warnings and precautions in the label.\footnote{305}{Id. at 3.} The agency also noted that the brand-name company’s label specifically states that, “[t]he clinical relevance of these effects is unknown,” thus implicating no issues of safe use.\footnote{306}{Id. at 3 n.3.} With the “Dear Applicant” letter in hand, the generic appeared to have a clear path to a successful carve-out.
Immediately thereafter, however, the brand-name company submitted multiple citizen petitions challenging the contents of the FDA’s “Dear Applicant” letter. At this point, instead of wading into a new battle over section viii carve-outs, the generic applicant filed Paragraph IV certifications for the two new patents in late 2004, triggering litigation with the brand-name company. While the lawsuit was underway, the brand-name company worked to strengthen its labeling position, receiving approval for a new label in 2006 which removed the sentence about unknown clinical relevance and added the following sentence to the Precautions section of the label: “Taking SKELAXIN with food may enhance general [central nervous system] depression; elderly patients may be especially susceptible to this CNS effect.”

Now, the brand-name company had a label with a patent-protected precaution implicating safe use for a drug with only one indication, posing a difficult problem for the generic and the FDA. As the FDA admitted, “[c]arving out patent-protected language from the Precautions section of a label that pertains to a labeled use would generally not be permitted.”

The FDA, at an impasse, essentially chose to punt on the issue, making no decision on the brand-name company’s citizen petitions. Instead, closure eventually came from the courts five years later, when a Brooklyn-based district court judge invalidated the two bioavailability patents. The judge held that, given what was already known about the drug, it was obvious that Skelaxin would be better absorbed if taken with food. Thus, the generic won its Paragraph IV challenge, and the FDA approved the generic application in 2010, making the carve-out discussion entirely moot.

The delay earned by the brand-name company, however, was not a moot point. From the date that the FDA accepted the first generic application to the date of approval, the brand-name company’s tactics delayed the entry of generic Skelaxin for almost a decade, despite the fact that the company lost. The delay may have been worth as much as $3 billion in sales—all
over one sentence on a label and two patents claiming the supposedly novel finding that Skelaxin is better absorbed when taken with food.

VI. Conclusion: Earning a Better Grade for Hatch-Waxman

Thirty years of the Hatch-Waxman regime have brought an extraordinary revolution in the introduction of generic drugs. The progress, however, has not been without resistance. As described above, pharmaceutical companies have engaged in three waves of behaviors to stave off generic competition as long as possible. The first generation involves paying generic companies to delay their entry into the market—that is, sharing a portion of monopoly profits with a generic in exchange for an agreement to delay competition. With antitrust scrutiny of such behaviors on the horizon, pharmaceutical companies developed a further generation of behaviors centered on multiple side deals, in which the companies settle many cases at once or agree to provide overvalued or undervalued services to each other as a way to camouflage the value of the transfers occurring in exchange for delayed entry. Each of these approaches is a clever way to try to obfuscate the nature of the behavior. Finally, Generation 3.0 games no longer focus on colluding with generic competitors; instead, the games rely on micro-obstructions against generic companies. These include using administrative processes, regulatory schemes with connections to Hatch-Waxman, and drug modifications to obstruct generics from getting to market. Further, they often combine a number of these tactics to create a multiplicity effect. Micro-obstructions are devilishly difficult to detect and deter. Of course, Generations 3.0 and 2.0 can be combined by developing obstructive behaviors and then promising not to engage in them, using what this article calls boy scout clauses.

Of all of the approaches, the boy scout clauses are perhaps the most cynical. Here, a brand-name company engages in collusive behavior to avoid competition while trying to insulate itself from attack by claiming that it is behaving honorably. While boy scout clauses may be particularly cynical, however, all of the Generation 3.0 approaches threaten a new wave of behaviors that will be difficult for Congress, the courts, and regulatory agencies to control.

average yearly Skelaxin sales of $357 million. The first full year in which Skelaxin faced a pending ANDA was 2002, while 2009 was the last full year before generic approval. Then, $357 million was multiplied by 9, representing approximately 9 years of delay, to reach a total value of $3.2 billion. Press Release, King Pharm., King Pharmaceuticals Acquires Primary Care Business Unit from Elan (Jan. 30, 2003), http://www.sec.gov/Archives/edgar/data/1047699/000095014403000944/g80411exv99w1.txt [https://perma.cc/SFYD-7VCG] (noting 2002 sales of $238 million); Press Release, Sandoz, Sandoz Announces Launch of First Generic Version of Leading Muscle Relaxant Skelaxin (May 20, 2010), http://www.fiercepharma.com/press-releases/sandoz-announces-launch-first-generic-version-leading-muscle-relaxant-skela
Drug Wars

A. Societal Harms

The strategic behaviors in the Hatch-Waxman arena are troubling from the perspective of the theoretical underpinnings of both patent and antitrust law. The patent concern traces back to the constitutional provision that frames all of patent law. From the activities that should be free to all and reserved to none, the patent system chooses to dedicate to some, for a limited period of time, the exclusive use of an innovation based on the theory that this exclusion will redound to the benefit of society.315 The bargain, however, is not unlimited. When the patent expires, everyone should be free to engage in those activities, returning to a competitive environment. Hatch-Waxman is intended to ensure the prompt return to a competitive environment at the end of the patent term, as well as to create incentives to weed out weak patent claims that are improperly keeping competitors out of the particular innovative space. Pharmaceutical company behavior that extends the period in which the company can hold off competition runs contrary to the patent bargain.

The behaviors described in this article also raise antitrust concerns, although those concerns are framed at a slightly different angle.316 As a general matter in antitrust doctrine, big is not bad; it is what you do with your size that matters.317 Thus, brand-name companies that have earned a monopoly in the market with their blockbuster drugs are targets of antitrust concern only when they attempt to extend their monopoly improperly by colluding with competitors or inappropriately suppressing competition. As scholarly works by this author and others have noted, agreements not to compete and activities that abuse the regulatory process to block competitors raise antitrust concerns.318 Thus, when pharmaceutical company behavior improperly delays or impedes the entry of generic competition, that behavior runs contrary to the open, competitive market environment for which antitrust law yearns.

The theoretical concerns translate into tangible damage to society as well. With patents, the legal system chooses to tolerate certain societal losses for the innovation effects that may result. When brand-name companies extend their monopoly power beyond the expiration of the patent, however, there are unanticipated deadweight losses to society in the form of higher prices. Whether Congress has chosen the optimal parameters for the patent


316 For a discussion of the differing perspectives of patent law and antitrust law regarding inappropriate behavior by patent holders, see generally Feldman, supra note 67.


318 See, e.g., id. at 26–33; Carrier, Levidow & Kesselheim, supra note 198, at *31; Hemp-hill, An Aggregate Approach to Antitrust, supra note 53, at 10.
system is a separate question. Once those parameters are set, behaviors that cause additional deadweight losses for society are contrary to the system’s incentive structure, and the damage to society should not be tolerated.

The Hatch-Waxman manipulations also are damaging to society in the form of activities that are wasteful for companies and institutions alike. Hide-and-seek games that the courts, the FDA, the FTC, and the Patent and Trademark Office are forced to play are wasteful to all. The games are particularly burdensome on the court system, with pharmaceutical litigation over generic competition now joining patent troll litigation as a major component of new patent lawsuit filings.319 Sadly, given the amount of money at stake, the behaviors are likely to continue unless the legal system finds a way to change the incentives or to create sufficient disincentives. This is not to suggest that progress has been negligible. The shift from simple pay-for-delay agreements to side deals and then to micro-obstructions reflects the progress that regulatory agencies have begun to achieve in the courts. In addition, although micro-obstructions can create a valuable delay in competition, they are more difficult to achieve and often less lengthy than pay-for-delay.

Nevertheless, although the form of the behavior may have shifted, the behavior remains. And although changes such as the Supreme Court decision in *Actavis* and various congressional amendments have been important, by the time the changes are implemented, the market has moved beyond. The question is, what should come next.

The following discussion explores new directions for the legal system in its continuing efforts to alleviate the gamesmanship that the Hatch-Waxman system has wrought. The discussion is not intended to provide a blueprint for legislation or a description of specific doctrinal provisions. Rather, it is an attempt to suggest the contours of how new approaches could be structured, and to generate discussion of a shift in approach.

### B. Systems, Simplification, Sunshine, and Standards-Based Doctrines

In addition to the approaches that have been undertaken so far, managing the evolution of the Hatch-Waxman games will require a systems approach. One could use an analogy from the medical field itself.320 Under the old approach to cancer treatment, physicians would attack a tumor by trying

---


320 This system theory example is taken from Robin Feldman, *Cultural Property and Human Cells*, 21 INT’L J. CULTURAL PROP. 1, 6 (2014).
to reduce its size or deny substances that seemed to be feeding it. Modern medical research has suggested, however, that cancer treatment can be far more effective when using a systems approach. Specifically, tumors seem to operate in a networked or systems fashion. Cutting off one approach may simply lead the tumor to develop work-around approaches, and the new approaches may be even more dangerous and damaging than the original pathway. Thus, attacking the problem by trying to mitigate it when it emerges may be as outdated an approach for the patenting and approval of medicines as it is for treatments in which those medicines will be involved.321

Taking a systems approach may allow us to move away from what one of the authors has called death by tinkering—a problem endemic throughout the patent system.322 In this problematic approach, legal actors address difficult questions by adjusting the doctrines a little here and a little there without developing a comprehensive logic for the full breadth of the legal area. Eventually, the entire doctrinal base threatens to collapse under its own weight.

One can see a classic example of death by tinkering in the Federal Circuit’s failed attempts to create a workable rule for determining what types of inventions should qualify as patentable subject matter. For years, the court clung to its “machine-or-transformation” test, making ever finer distinctions to try to avoid uncomfortable results. In the end, the test required considerable hand waving, and one had to suspend a certain amount of disbelief to overlook the logical discrepancies.323 After a series of three cases gently encouraging the Federal Circuit to develop a workable test, the Supreme Court eventually gave up and supplied its own test.324

A similar phenomenon plagues the various doctrines related to whether the definition of an invention reaches beyond the state of the art at the time of the invention. Doctrines developed for mechanical inventions, in which one generally understands all aspects of the technology, have led to uncomfortable results for biologic inventions, in which many unknown factors may


322 See Robin Feldman, A Conversation on Judicial Decision-Making, 5 Hastings Sci. & Tech. L.J. 1, 2 (2013) (introducing the concept in the context of Federal Circuit attempts to fix problems in patent doctrines such as patentable subject matter without taking into account the doctrinal area as a whole).


be at play. For example, when an invention is a doorknob, one generally understands the various parts and their operation. There are no unexplained pieces and no hints that the door frame may be integrating with the door in ways no one has dreamed.³²⁵ Such is not the case with biotechnology inventions, however, and in that realm, society grants rights in the face of significant unknowns.

Doctrinal rules that fit comfortably with mechanical inventions can lead to uncomfortable results in life science cases. Struggling with the problem, different Federal Circuit panels have created doctrinal rules that contradict each other and point in different theoretical directions.³²⁶ The rules reach what seem to be good results in each case, but at the expense of doctrinal coherence and the ability to predict the boundaries of patents going forward. The entire area now threatens to collapse. Doctrines related to defining an invention for purposes of comparing it to later inventions are clashing against doctrines related to defining the invention for purposes of comparing it to earlier inventions. Unless one is happy holding up a piece of fruit and declaring that looking in one direction, it is an apple, and looking in another direction, it is an orange, the doctrines are untenable.³²⁷

Therefore, the first step in a systems approach would involve focusing on the extent to which different systems interact in the process. These include not only the patent approval system, but also the patent litigation system,³²⁸ FDA approval systems—including the Orange Book, REMS, citizens petitions, and other FDA processes—and antitrust doctrines as they may apply to this arena. Effective progress will require working with all of these systems at the same time, lest adjustments to one area lead to counteraction in another. With thirty years of Hatch-Waxman experience, it is time to consider a comprehensive overhaul of the system for generic approval, one that looks more broadly at the interaction of all of the systems.

The second step is to ruthlessly simplify. For those who value complexity, the Hatch-Waxman system is a garden of delights. Complexity breeds opportunity, however, and, in the case of Hatch-Waxman, the Act’s complexity has spawned opportunities for manipulation. An overhaul of the Hatch-Waxman system that resulted in equivalent or even greater complexity would serve little purpose, other than as a full employment act for lawyers. In contrast, a simplified, slimmed-down system would provide fewer opportunities for clever gamesmanship, as well as absorbing fewer resources for the system as a whole.

³²⁵ The doorknob example is described more fully in Robin Feldman, Rethinking Rights in Biospace, 79 So. Cal. L. Rev. 1, 8–12 (2006).
³²⁶ For a more extensive discussion of the clash of doctrines described in this paragraph, see Feldman, supra note 13, at 189–208.
³²⁷ See id. at 207.
³²⁸ In light of the introduction of more robust forms of post grant review in the 2011 patent reform America Invents Act, a comprehensive approach would also need to consider how those systems interact with Hatch-Waxman and how they could be used for gamesmanship.
From this perspective, the 2009 Biologics Price Competition and Innovation Act ("BPCIA," also commonly known as the "Biologics Act") is not encouraging. The legislation was intended to provide a pathway for swift approval of biosimilars, or what could be called generic biologic drugs, in the same way that Hatch-Waxman provided a speedier pathway for ordinary generic drugs. Biologics are complex cell-derived drugs that include antibodies that fight autoimmune diseases and proteins that boost white blood cell counts during chemotherapy. The Biologics Act, however, is even more complex and convoluted than Hatch-Waxman and seems designed on entirely the wrong template.329 It took until September 2015—six years after the act’s passage—for the first biosimilar to reach the market.330

Simplification is not the instinct of lawyers in general nor of patent lawyers in particular. Lawyers are trained to see the nuances in any circumstance and may wish to keep options open for whatever their clients need. Moreover, the patent bar has never been accused of an attraction to exorbitant simplicity. Overcoming these instincts, which are deeply imbedded in the habits of patent stakeholders, will be an essential component of designing a more effective system.

The third step is to let the sun shine in. Both markets and regulators work best when information is fully available—information that invites competition where competition is needed and exposes behavior that regulators can challenge. Moreover, in a world of instant communication, information plays a powerful role in disciplining behavior. Information in pharmaceutical deals and pricing is increasingly segmented, however, and hidden from key players in the industry—whether those players are competitors, regulators, or consumers.

In particular, pharmaceutical pricing is not necessarily drug-specific anymore. Rather, pharmaceutical benefit managers, known as “PBMs,” negotiate the prices for the vast majority of commercially insured drug purchases.331 In other words, PBMs are third-party intermediaries that negotiate drug prices between payers and others. This frequently results in bundled drug pricing, tucked into which may be pricing that reaps supra-competitive rewards or blocks generic competition. For example, a drug company could offer attractive discounts on one drug in exchange for pricing or listing practices that block competition where prices are elevated or competition would be a greater threat.

329 See generally Jason Kanter & Robin Feldman, Understanding and Incentivizing Biosimilars, 64 Hastings L.J. 57 (2012) (analyzing and identifying issues with the Biosimilars Act).


None of this information is available, either to the market or to regulators. The pharmaceutical ecosystem would benefit tremendously from sunshine rules that require disclosure of PBM pricing deals and rebates. This is not to suggest regulation of pricing, but rather to provide the information that markets and regulators need for efficient functioning.

A fourth step would be to move away from the Supreme Court’s rule of reason analysis for pharmaceutical deals that involve generics. Despite the opening that the Supreme Court created in *Actavis*, the lower courts largely have been unable or unwilling to walk through it. The burden remains too great for anyone to bear. Rather, with deals involving generic entry, Congress should place the burden on those making the deals to show that they are proper.\(^{332}\) The taint of anticompetitive behavior is too strong throughout these arrangements, and the extent to which these deals undermine Hatch-Waxman’s intent to introduce generics early and often is too great. One who creates complexity, and the resultant capacity to hide behind that complexity, should have the burden to demonstrate that the effects are justifiable.

The most important step, however, is to make more liberal use of standards-based legal doctrines. The Hatch-Waxman system and its various amendments have tended to focus on precise and particularized legal rules. Brand-name drug companies are forbidden from receiving more than one thirty-month stay; the FDA must take final action on a citizen petition in 150 days.

Some fixes have leaned toward the standards approach. For example, the FDA’s ability to deny a citizen petition at any time if it believes a petition was “submitted with the primary purpose of delaying the approval of an application” is an excellent standards-based approach. The amendment granting that power, however, goes on to require that the “petition does not on its face raise valid scientific or regulatory issues,”\(^{333}\) a provision that moves back toward the realm of rule-based approaches.

A classic standards-based approach can be found in the tax code’s step transaction doctrine. The doctrine allows tax authorities to collapse all the steps of a transaction together if the authority deems that they are part of an overall plan by the taxpayer.\(^{334}\) The doctrine is aimed at ensuring that taxpayers may not avoid legal restrictions by taking individual steps or a circuitous route.\(^{335}\) A more liberal use of this type of standards-based approach could give courts and regulators the latitude to shut down strategic behavior, as opposed to playing cat and mouse across the regulatory provisions.

\(^{332}\) At least two bills have recently been introduced that would begin to shift the burden for some pay-for-delay settlements. See *Preserve Access to Affordable Generics Act, S. 2019, 114th Cong.* (2015); *Prescription Drug Affordability Act of 2015, S. 2023, 114th Cong.* (2015).


\(^{334}\) See Feldman, *Intellectual Property Wrongs*, supra note 275, at 310 (describing the value of using this type of doctrine in the patent context).

\(^{335}\) *Id.*
One should not be overly optimistic. From a political economy perspective, the pressure on members of Congress to avoid an overhaul of the system—let alone a simplified approach that will close off strategic behavior—will be great. When Congress tried to block Hatch-Waxman strategic behaviors in the 2003 amendments to the Act, Congressman Henry Waxman, one of the original authors of the Act, addressed the pharmaceutical industry:

I call upon the brand-name industry to cease and desist from inventing new games, and that they return to the scientific research that they are good at and that has been their real contribution.336

The Congressman’s comments appear to have been in vain. Nevertheless, a comprehensive overhaul of Hatch-Waxman, that takes a systems perspective, focuses on simplification, and includes a healthy dose of standards-based authority, could go a long way toward bringing these drug wars under control. After thirty years of experience with Hatch-Waxman, it is time for the next phase.
